AOCNP Practice Test

Advanced Oncology Certified Nurse Practitioner (AOCNP®)

AOCNP overview

  • 200 practice questions
  • 32 flashcards
  • 5 study guide topics
  • 40 key terms

What you'll study

  • Science of Oncology20%
  • Cancer Prevention, Detection, and Diagnosis20%
  • Cancer Treatment Modalities20%
  • Supportive, Palliative, and End-of-Life Care20%
  • Survivorship and Coordination of Care20%

The Advanced Oncology Certified Nurse Practitioner (AOCNP®) credential is offered by the Oncology Nursing Certification Corporation (ONCC), a certification body for nurses in oncology and related specialties. It is designed for advanced practice registered nurses - nurse practitioners - who manage patients with cancer across the care continuum, and it signals validated, current oncology knowledge to patients, employers, and interdisciplinary teams. ONCC describes certification as deepening knowledge and care across oncology and strengthening patient trust in cancer care.

The exam is multiple choice, and ONCC publishes practice tests built from the same item types and styles candidates will encounter on the real examination. Content spans the breadth of advanced oncology practice: the science of oncology; cancer prevention, detection, and diagnosis; treatment modalities; supportive, palliative, and end-of-life care; and survivorship and coordination of care. Expect items that test clinical decision-making within the APRN scope of practice rather than isolated recall.

Preparation works best as a staged plan: review ONCC's test resources and content outline first, take a practice test to find weak domains, then study by domain and re-test. ONCC's practice tests include the correct answer, rationale, and reference for every item, which makes them useful as learning tools rather than just score checks. Verify eligibility, deadlines, and scheduling directly with ONCC; this page is independent study material and is not affiliated with or endorsed by ONCC.

Common mistakes

On any item naming a leukemia, lymphoma, plasma cell dyscrasia, or gynecologic cancer, defaulting to solid-tumor TNM logic - e.g., calling Ann Arbor stage IV lymphoma 'metastatic to a distant organ,' or treating Rai stage 0 CLL as advanced disease.

TNM is learned first and becomes the automatic mental template; the alternative systems are memorized as isolated fact lists without the trigger that tells you which system is in play.

What to do instead

Before choosing an answer, name the staging system out loud from the histology (Ann Arbor = lymphoma, Rai/Binet = CLL, FIGO = gynecologic, ISS/R-ISS = myeloma, TNM = solid tumor), then recall the single variable that defines that system's stages (B symptoms and nodal regions, absolute lymphocyte count, beta-2 microglobulin, tumor size/nodes/metastasis).

Treating a single-arm phase II response rate as evidence of survival benefit, or naming overall survival as the endpoint that must be met for accelerated approval, or saying a phase I trial establishes efficacy.

Phase names are memorized as a sequence without attaching each phase to its question (safety/dose vs. activity vs. comparative benefit) and its typical design (single-arm vs. randomized).

What to do instead

Map each phase to one question before answering: phase I = dose, safety, MTD/DLT; phase II = does it shrink tumors in this histology (response rate, single-arm allowed); phase III = does it improve a hard outcome versus a comparator (randomized; OS is the gold standard, PFS/ORR may support accelerated approval with confirmatory follow-up).

Applying average-risk screening intervals to a patient whose stem contains a risk qualifier - e.g., a 10-year colonoscopy interval after a prior advanced adenoma or in Lynch syndrome, or starting mammography at 40 in a known BRCA carrier with no MRI.

The average-risk schedule is heavily overlearned and the risk qualifier is usually buried in a subordinate clause of the history rather than in the question itself.

What to do instead

Scan the stem for three triggers before selecting a test or interval - personal cancer/precursor history, family history (and age at diagnosis), and germline mutation - assign the patient to a risk tier first, then pull the interval from a memorized high-risk list kept separate from the average-risk list.

Choosing CA-125, CEA, CA 19-9, or LDH as the answer to 'what test should be used to screen for' or 'what establishes the diagnosis,' and accepting a PET/CT as diagnostic of a new primary without tissue.

These markers have strong associative links to specific cancers in memory, so they feel correct regardless of whether the question is asking about screening, diagnosis, monitoring, or surveillance.

What to do instead

Classify the purpose of the test first - screening in an asymptomatic population, diagnosis, staging, or surveillance of known disease - and only then match the test; tissue is required to establish a new primary unless the stem describes a validated exception (e.g., a marker-plus-imaging pathway in a specific clinical scenario).

In febrile neutropenia, choosing to repeat cultures, wait for results, or give a non-antipseudomonal regimen, or adding vancomycin reflexively to every case.

General infectious-disease habits (culture before treating, tailor to results) and the desire to be 'targeted' conflict with the oncology rule that time-to-antibiotic drives mortality; vancomycin overuse comes from confusing line infections with all neutropenic fevers.

What to do instead

Memorize one threshold-plus-timer pair: a single oral temperature of 38.3 C or a sustained 38.0 C over one hour with an ANC under 500 means an antipseudomonal beta-lactam within 60 minutes, cultures drawn on the way to the antibiotic, not before it. Add vancomycin only for catheter-site infection, skin/soft tissue infection, pneumonia, or hemodynamic instability.

Continuing a checkpoint inhibitor while 'watching' grade 2 or 3 immune-mediated colitis, hepatitis, or hypophysitis, or reserving steroids for grade 4 toxicity.

Cytotoxic chemotherapy habits carry over - hold only for grade 3 or 4 marrow toxicity - but immune-related adverse events have much lower intervention thresholds and are treated with immunosuppression rather than dose delay alone.

What to do instead

Replace the chemo reflex with a grade-based irAE table: grade 2 gastrointestinal or hepatic toxicity means hold the drug and start corticosteroids; grade 3 means hold plus high-dose steroids; grade 4 (excluding some endocrinopathies) means permanent discontinuation. Endocrine irAEs are managed with hormone replacement rather than drug discontinuation in most cases.

For a patient reporting 7-10/10 cancer pain, selecting a weak opioid or an NSAID, or refusing to escalate the dose because the patient 'is already on opioids,' and converting between opioids without adjusting for incomplete cross-tolerance.

Opioid-phobia transfers from general practice, and equianalgesic conversion is often memorized as a single ratio rather than a table with a safety adjustment step.

What to do instead

Separate the two concepts in your own words before answering - tolerance and physical dependence are expected pharmacology, not addiction - and treat severe pain with a strong opioid titrated to effect. For any switch, use the standard equianalgesic row for the two drugs involved and then reduce the calculated new dose by 25-50% for incomplete cross-tolerance.

Answering with the definitive diagnostic or definitive-treatment option when the question asks for the immediate next action - e.g., ordering MRI before giving dexamethasone in a patient with known malignancy, new back pain, and leg weakness.

The most sophisticated-sounding option feels like the best answer, and the frame word ('next,' 'immediate,' 'priority') is a single word in the final sentence that is easy to skim past.

What to do instead

Re-read the last sentence and underline its frame - next/immediate/priority versus best diagnostic test versus definitive management. Where a reversible emergency is on the differential (cord compression, SVC syndrome, tumor lysis, hypercalcemia), the stabilizing step precedes the confirmatory imaging or oncology treatment.

Prescribing intensive surveillance for an asymptomatic survivor beyond what the guideline recommends - routine PET in treated lymphoma, indefinite tumor-marker and CT testing after resected colon cancer, or serial scans with no symptom or marker trigger.

Surveillance is assumed to follow the same logic as treatment response assessment, and 'more monitoring is safer' is a strong intuitive pull that is not supported for most curatively treated cancers.

What to do instead

Anchor each answer to the named cancer's surveillance regimen and its stop date (for example, colon cancer: CEA every 3-6 months and CT annually, both for about 5 years), and apply the general principle that surveillance is visit- and symptom-driven with modality-specific intervals; escalating imaging in an asymptomatic patient with normal markers is usually the wrong choice.

Advising a patient of reproductive potential to finish chemotherapy first and address fertility afterward, assuming an older or very young patient does not need a referral, or telling a patient it is safe to conceive while on endocrine therapy.

Fertility is filed mentally as a post-treatment quality-of-life issue rather than a time-critical pretreatment decision, and coordination failures are easy to make when the question is framed around starting therapy quickly.

What to do instead

Trigger on any patient with reproductive potential facing gonadotoxic therapy: refer to reproductive endocrinology and document the discussion before cycle one, recognizing that oocyte or embryo cryopreservation takes roughly two weeks and ovarian suppression is an adjunct rather than a substitute. Also state that pregnancy is avoided during endocrine therapy and for the drug-specific washout interval afterward.

Exam requirements can change. Confirm current details with the exam provider.

AOCNP practice

200 questions. Each one lists the choices, the correct answer, and an explanation. With JavaScript, this list opens one question at a time. The checker at the top of this page saves progress in this browser when it is available.

  1. Question 1Science of Oncology

    Which term describes the ability of a malignant cell to spread from its original site to a distant organ?

    1. Angiogenesis
    2. Apoptosis
    3. Metastasis Correct answer.
    4. Invasion

    Explanation

    Metastasis is the process by which cancer cells disseminate from a primary tumor, survive in the circulation or lymphatics, and establish growth at a distant site. Invasion refers to local extension through tissue barriers, not distant spread.

  2. Question 2Science of Oncology

    A mutation that inactivates a tumor suppressor gene most directly promotes cancer by:

    1. Increasing DNA repair fidelity
    2. Activating a growth factor receptor
    3. Enhancing immune surveillance
    4. Removing a brake on cell-cycle progression Correct answer.

    Explanation

    Tumor suppressor genes normally restrain proliferation, repair DNA, or promote apoptosis; loss of function removes these restraints. Oncogenes, in contrast, are activated by gain-of-function mutations.

  3. Question 3Science of Oncology

    Which class of gene is activated by a gain-of-function mutation that drives unregulated cell proliferation?

    1. DNA mismatch repair gene
    2. Tumor suppressor gene
    3. Proto-oncogene Correct answer.
    4. Apoptosis effector gene

    Explanation

    A proto-oncogene becomes an oncogene when gain-of-function mutations or amplifications cause excessive or constitutive growth signaling. Tumor suppressor and DNA repair genes generally require loss of function to promote cancer.

  4. Question 4Science of Oncology

    The G1/S checkpoint primarily prevents a cell from:

    1. Exiting quiescence after nutrient signals
    2. Entering S phase with damaged DNA Correct answer.
    3. Separating chromatids during anaphase
    4. Repairing double-strand breaks by recombination

    Explanation

    The G1/S checkpoint assesses DNA integrity and cell size before DNA replication begins. Cells with unrepaired DNA damage arrest before S phase to allow repair.

  5. Question 5Science of Oncology

    Which route of metastasis is most characteristic of carcinomas spreading to regional lymph nodes?

    1. Transcoelomic spread
    2. Perineural spread
    3. Hematogenous spread
    4. Lymphatic spread Correct answer.

    Explanation

    Carcinomas commonly metastasize first through lymphatic channels to regional lymph nodes. Sarcomas more often spread hematogenously, while transcoelomic and perineural patterns are seen in selected tumors.

  6. Question 6Science of Oncology

    Which statement best distinguishes tumor grade from tumor stage?

    1. Grade reflects differentiation; stage reflects anatomic extent. Correct answer.
    2. Grade reflects anatomic extent; stage reflects differentiation.
    3. Grade applies only to leukemias; stage applies only to solid tumors.
    4. Grade is set by tumor markers; stage is set by biopsy.

    Explanation

    Grade describes how closely tumor cells resemble normal tissue and how rapidly they appear to divide. Stage describes the anatomic extent of disease, including tumor size, nodal involvement, and metastasis.

  7. Question 7Science of Oncology

    A patient with small cell lung cancer develops hyponatremia from ectopic ADH. Which paraneoplastic syndrome is this?

    1. Parathyroid hormone-related peptide causing hypercalcemia
    2. Antidiuretic hormone causing hyponatremia Correct answer.
    3. Ectopic corticotropin causing Cushing syndrome
    4. Serotonin causing carcinoid syndrome

    Explanation

    Small cell lung cancer can secrete ectopic antidiuretic hormone, producing SIADH with euvolemic hyponatremia. This is distinct from ectopic ACTH, PTHrP-mediated hypercalcemia, or serotonin excess.

  8. Question 8Science of Oncology

    After myelosuppressive chemotherapy, the neutrophil count typically reaches its nadir at approximately which time?

    1. 21 to 28 days
    2. 7 to 14 days Correct answer.
    3. 24 hours
    4. 3 to 5 days

    Explanation

    The neutrophil nadir after many myelosuppressive regimens occurs at about 7 to 14 days, depending on the drugs used. Counts usually recover by around 21 to 28 days.

  9. Question 9Science of Oncology

    Overexpression of BCL-2 in a lymphoma cell promotes malignancy mainly by:

    1. Accelerating DNA replication
    2. Increasing antigen presentation
    3. Blocking cytochrome c release and apoptosis Correct answer.
    4. Activating caspase-8 at death receptors

    Explanation

    BCL-2 is an antiapoptotic mitochondrial protein that prevents cytochrome c release and caspase activation. This allows malignant lymphocytes to survive instead of undergoing programmed cell death.

  10. Question 10Science of Oncology

    Vascular endothelial growth factor contributes to tumor progression primarily by:

    1. Increasing mismatch repair activity
    2. Activating proto-oncogenes inside tumor cells
    3. Promoting antibody-dependent cellular cytotoxicity
    4. Stimulating endothelial growth and vessel leakiness Correct answer.

    Explanation

    VEGF drives angiogenesis by stimulating endothelial cell proliferation, survival, and vascular permeability. These new vessels support tumor growth and can facilitate dissemination.

  11. Question 11Science of Oncology

    Binding of PD-L1 on tumor cells to PD-1 on T cells produces which effect?

    1. Enhanced T-cell receptor signaling
    2. Complement-mediated tumor lysis
    3. Reduced T-cell activation and effector function Correct answer.
    4. Increased major histocompatibility complex expression

    Explanation

    PD-L1 engagement of PD-1 delivers an inhibitory signal that dampens T-cell activation, proliferation, and cytotoxic function. Tumors exploit this checkpoint to evade immune attack.

  12. Question 12Science of Oncology

    A germline BRCA1 mutation chiefly increases cancer risk by impairing which process?

    1. Homologous recombination repair Correct answer.
    2. Base excision repair of oxidized bases
    3. Mismatch repair of replication errors
    4. Nucleotide excision repair of bulky adducts

    Explanation

    BRCA1 and BRCA2 are required for homologous recombination repair of DNA double-strand breaks. Loss of this pathway causes genomic instability and predisposes to breast, ovarian, and other cancers.

  13. Question 13Science of Oncology

    Lynch syndrome is caused by a germline defect in which DNA repair pathway?

    1. Mismatch repair Correct answer.
    2. Homologous recombination
    3. Nucleotide excision repair
    4. Nonhomologous end joining

    Explanation

    Lynch syndrome results from germline mutations in mismatch repair genes such as MLH1, MSH2, MSH6, or PMS2. Deficient mismatch repair leads to microsatellite instability and increased colorectal and endometrial cancer risk.

  14. Question 14Science of Oncology

    The Philadelphia chromosome in chronic myeloid leukemia creates which fusion gene?

    1. MYC-IGH
    2. PML-RARA
    3. EML4-ALK
    4. BCR-ABL1 Correct answer.

    Explanation

    The Philadelphia chromosome arises from a t(9;22) translocation that fuses BCR with ABL1. The resulting BCR-ABL1 tyrosine kinase drives chronic myeloid leukemia and is targeted by tyrosine kinase inhibitors.

  15. Question 15Science of Oncology

    Which tumor marker is most useful for monitoring disease activity in epithelial ovarian cancer?

    1. Alpha-fetoprotein
    2. Calcitonin
    3. CA-125 Correct answer.
    4. Carcinoembryonic antigen

    Explanation

    CA-125 is commonly elevated in epithelial ovarian cancer and is used to follow disease response or recurrence. It is not diagnostic by itself and can be elevated in other conditions.

  16. Question 16Science of Oncology

    A drug metabolized primarily by CYP3A4 is likely to have increased exposure when coadministered with which agent?

    1. Ketoconazole Correct answer.
    2. Phenytoin
    3. St. John's wort
    4. Rifampin

    Explanation

    Ketoconazole is a strong CYP3A4 inhibitor and can reduce metabolism of CYP3A4 substrates, increasing their plasma concentrations and toxicity risk. Rifampin, phenytoin, and St. John's wort are enzyme inducers.

  17. Question 17Science of Oncology

    Taxanes exert their cytotoxic effect mainly during which phase of the cell cycle?

    1. S phase
    2. G1 phase
    3. M phase Correct answer.
    4. G0 phase

    Explanation

    Taxanes stabilize microtubules and disrupt mitotic spindle dynamics, causing arrest and cell death during mitosis. They are therefore classified as M-phase cell-cycle-specific agents.

  18. Question 18Science of Oncology

    The oxygen enhancement ratio reflects that hypoxic tumor cells are:

    1. Equally sensitive to radiation regardless of oxygen
    2. Protected from radiation by antioxidant enzymes
    3. More resistant to radiation than oxygenated cells Correct answer.
    4. More sensitive to radiation than oxygenated cells

    Explanation

    Oxygen fixes radiation-induced free radical damage, so well-oxygenated cells are more radiosensitive. Hypoxic cells are relatively radioresistant, which contributes to treatment failure.

  19. Question 19Science of Oncology

    Which laboratory abnormality is most characteristic of tumor lysis syndrome?

    1. Hypokalemia with hypophosphatemia and hypouricemia
    2. Hyperuricemia with hyperkalemia and hyperphosphatemia Correct answer.
    3. Hypercalcemia with hypernatremia and metabolic alkalosis
    4. Hypouricemia with hypokalemia and metabolic acidosis

    Explanation

    Tumor lysis syndrome results from rapid release of intracellular contents and is characterized by hyperkalemia, hyperphosphatemia, and hyperuricemia, often with hypocalcemia. These abnormalities can cause renal failure and arrhythmias.

  20. Question 20Science of Oncology

    Which cytokine is most strongly implicated in cancer cachexia and anorexia?

    1. Tumor necrosis factor-alpha Correct answer.
    2. Transforming growth factor-beta
    3. Interferon-gamma
    4. Interleukin-4

    Explanation

    Tumor necrosis factor-alpha, often along with interleukin-6 and other inflammatory cytokines, contributes to anorexia, muscle wasting, and metabolic derangement in cancer cachexia.

  21. Question 21Science of Oncology

    The Warburg effect describes which metabolic phenotype of cancer cells?

    1. Exclusive reliance on oxidative phosphorylation for ATP
    2. Increased fatty acid oxidation with reduced glucose uptake
    3. High glycolytic flux to lactate despite adequate oxygen Correct answer.
    4. Complete glucose oxidation through the citric acid cycle

    Explanation

    The Warburg effect is aerobic glycolysis: cancer cells convert glucose to lactate even when oxygen is available. This supports biosynthesis and provides a metabolic advantage in the tumor microenvironment.

  22. Question 22Science of Oncology

    PARP inhibitors are selectively lethal to BRCA-deficient cancer cells because:

    1. PARP inhibitors hyperactivate mismatch repair
    2. Combined loss of homologous recombination and single-strand break repair is lethal Correct answer.
    3. BRCA-deficient cells depend entirely on nucleotide excision repair
    4. PARP inhibition restores BRCA1 expression

    Explanation

    PARP inhibitors impair single-strand break repair, and BRCA-deficient cells cannot reliably repair the resulting double-strand breaks by homologous recombination. This synthetic lethality preferentially kills tumor cells with BRCA pathway defects.

  23. Question 23Science of Oncology

    Intratumor genetic heterogeneity most directly complicates cancer treatment by:

    1. Preventing acquisition of drug resistance
    2. Supplying resistant subclones before therapy starts Correct answer.
    3. Making all cells equally drug-sensitive
    4. Reducing the tumor mutational burden

    Explanation

    Genetic heterogeneity means that resistant subclones may already exist before treatment, allowing them to expand under selective drug pressure. This is a major reason for acquired resistance and treatment failure.

  24. Question 24Science of Oncology

    CTLA-4 blockade enhances antitumor immunity primarily by:

    1. Directly activating natural killer cells through Fc receptors
    2. Blocking PD-L1 on tumor cells
    3. Dampening inhibitory signals during T-cell priming Correct answer.
    4. Depleting regulatory T cells exclusively within tumors

    Explanation

    CTLA-4 competes with CD28 for costimulatory ligands and delivers inhibitory signals during early T-cell activation in lymphoid tissue. Blocking CTLA-4 lowers this threshold and broadens T-cell activation.

  25. Question 25Science of Oncology

    A liquid biopsy that detects circulating tumor DNA is most limited by which factor?

    1. Low tumor DNA fraction in early-stage disease Correct answer.
    2. Rapid extracellular degradation of cell-free DNA
    3. Requirement for fresh frozen tissue samples
    4. Inability to detect specific somatic mutations

    Explanation

    Circulating tumor DNA can represent a very small fraction of cell-free DNA, particularly in early-stage or low-burden disease, reducing sensitivity. Assays can detect specific mutations and use blood rather than fresh tissue.

  26. Question 26Science of Oncology

    In the classic multistep model of carcinogenesis, which sequence best describes the progression from a normal cell to a malignant cell?

    1. Dysplasia, initiation, angiogenesis
    2. Promotion, initiation, metastasis
    3. Initiation, promotion, progression Correct answer.
    4. Transformation, invasion, initiation

    Explanation

    Initiation creates irreversible genetic damage, promotion drives clonal expansion of the initiated cell, and progression involves the acquisition of invasive and malignant characteristics. The other sequences place later events before earlier ones and do not reflect the established model.

  27. Question 27Science of Oncology

    Which event most commonly activates a proto-oncogene into an oncogene?

    1. Silencing by promoter hypermethylation
    2. A single gain-of-function mutation Correct answer.
    3. Loss of heterozygosity
    4. Deletion of both alleles

    Explanation

    Oncogenes behave dominantly, so a gain-of-function change in one allele can be sufficient to promote growth. Tumor suppressor genes, by contrast, typically require inactivation of both alleles.

  28. Question 28Science of Oncology

    The two-hit hypothesis of tumor suppressor genes predicts that cancer develops when:

    1. A proto-oncogene is translocated to a new locus
    2. Both alleles of a tumor suppressor gene are inactivated Correct answer.
    3. One allele is amplified
    4. A single allele acquires a gain-of-function mutation

    Explanation

    Knudson's two-hit hypothesis states that both copies of a tumor suppressor gene must be inactivated before its protective function is lost. In hereditary syndromes, one hit is inherited and the second is acquired somatically.

  29. Question 29Science of Oncology

    The G1/S checkpoint prevents a cell from entering S phase when:

    1. The spindle assembly checkpoint is satisfied
    2. DNA is damaged or growth signals are low Correct answer.
    3. Chromosomes have aligned at the metaphase plate
    4. Cytokinesis has completed

    Explanation

    The G1/S checkpoint evaluates DNA integrity and the presence of adequate growth signals before committing the cell to DNA replication. p53 and the RB pathway are central to this decision.

  30. Question 30Science of Oncology

    HER2 amplification in breast cancer is best described as which mechanism of proto-oncogene activation?

    1. Promoter methylation causing silencing
    2. Point mutation causing constitutive activation
    3. Gene amplification causing overexpression Correct answer.
    4. Chromosomal translocation creating a fusion gene

    Explanation

    HER2 is activated by amplification of the gene, producing many copies and marked overexpression of the receptor. This excess receptor signaling drives proliferation and is targeted by trastuzumab and similar agents.

  31. Question 31Science of Oncology

    Which alteration most directly allows a cancer cell to evade apoptosis?

    1. Loss of p53 function Correct answer.
    2. Increased caspase-9 activity
    3. Increased expression of pro-apoptotic Bax
    4. Decreased expression of anti-apoptotic BCL-2

    Explanation

    p53 normally senses DNA damage and can trigger apoptosis, so loss of p53 function permits damaged cells to survive. This is a common mechanism by which tumor cells escape programmed cell death.

  32. Question 32Science of Oncology

    Epithelial-mesenchymal transition contributes to metastasis primarily by:

    1. Increasing tumor cell proliferation rate
    2. Reducing E-cadherin and gaining motility Correct answer.
    3. Enhancing immune recognition of tumor cells
    4. Promoting apoptosis of disseminated cells

    Explanation

    Epithelial-mesenchymal transition reduces E-cadherin-mediated adhesion and increases migratory and invasive capacity, allowing cells to leave the primary tumor. Proliferation and immune recognition are separate processes.

  33. Question 33Science of Oncology

    Xeroderma pigmentosum increases skin cancer risk because of a defect in which DNA repair process?

    1. Homologous recombination
    2. Nucleotide excision repair Correct answer.
    3. Mismatch repair
    4. Nonhomologous end joining of double-strand breaks

    Explanation

    Nucleotide excision repair removes bulky DNA lesions such as ultraviolet-induced pyrimidine dimers. When this pathway is defective, unrepaired UV damage causes mutations that predispose to skin cancers.

  34. Question 34Science of Oncology

    Tumor-associated macrophages in the tumor microenvironment most often promote progression by:

    1. Increasing tumor antigen presentation to T cells
    2. Secreting growth factors and suppressing immunity Correct answer.
    3. Directly killing tumor cells through phagocytosis
    4. Reducing angiogenesis and matrix remodeling

    Explanation

    Many tumor-associated macrophages adopt an immunosuppressive, M2-like phenotype that releases growth factors, cytokines, and proangiogenic molecules. This favors tumor growth, immune evasion, and remodeling of the microenvironment.

  35. Question 35Science of Oncology

    The three phases of cancer immunoediting are best described as:

    1. Initiation, promotion, progression
    2. Elimination, equilibrium, escape Correct answer.
    3. Presentation, activation, effector
    4. Recognition, anergy, tolerance

    Explanation

    Cancer immunoediting begins with elimination of immunogenic tumor cells, followed by an equilibrium phase of immune selection, and finally escape of variants that evade immune control. This framework explains how tumors persist despite immune surveillance.

  36. Question 36Science of Oncology

    Overexpression of P-glycoprotein in cancer cells confers resistance to chemotherapy by:

    1. Enhancing drug activation by cytochrome P450
    2. Actively effluxing drugs from the cell Correct answer.
    3. Preventing drug binding to tubulin
    4. Increasing drug uptake into the cell

    Explanation

    P-glycoprotein is an ATP-binding cassette transporter that pumps many hydrophobic chemotherapeutic agents out of the cell. Increased efflux lowers intracellular drug concentrations and produces multidrug resistance.

  37. Question 37Science of Oncology

    In fractionated radiotherapy, reoxygenation improves tumor cell killing because:

    1. It synchronizes tumor cells into the most radiosensitive phase
    2. It allows normal tissues to accumulate more damage
    3. It increases the total radiation dose delivered
    4. It makes surviving hypoxic cells more oxygenated Correct answer.

    Explanation

    Hypoxic cells are relatively radioresistant because oxygen is needed to fix radiation-induced DNA damage. Between fractions, surviving hypoxic cells can become reoxygenated and therefore more sensitive to subsequent doses.

  38. Question 38Science of Oncology

    A patient with a homozygous DPYD deficiency is at highest risk of severe toxicity from which chemotherapy agent?

    1. Doxorubicin
    2. Capecitabine Correct answer.
    3. Paclitaxel
    4. Cisplatin

    Explanation

    Dihydropyrimidine dehydrogenase, encoded by DPYD, catabolizes fluoropyrimidines such as 5-fluorouracil and its oral prodrug capecitabine. Deficient patients cannot clear the drug normally and are at high risk of severe myelosuppression, mucositis, and other toxicities.

  39. Question 39Science of Oncology

    Hypercalcemia in a patient with squamous cell lung cancer is most commonly caused by:

    1. Ectopic production of parathyroid hormone
    2. Excess 1,25-dihydroxyvitamin D production by tumor cells
    3. Tumor secretion of PTH-related peptide Correct answer.
    4. Osteoblastic metastases causing calcium release

    Explanation

    Squamous cell carcinomas often secrete parathyroid hormone-related peptide, which mimics parathyroid hormone and increases bone resorption and renal calcium reabsorption. This is the most common paraneoplastic cause of hypercalcemia in solid tumors.

  40. Question 40Science of Oncology

    High-risk human papillomavirus promotes cervical carcinogenesis mainly through which viral proteins?

    1. E5 and E6, which activate receptor tyrosine kinases
    2. E1 and E2, which regulate viral replication
    3. L1 and L2, which form the viral capsid
    4. E6 and E7, which inactivate p53 and RB Correct answer.

    Explanation

    The high-risk HPV oncoproteins E6 and E7 respectively promote degradation of p53 and inactivation of retinoblastoma protein, disrupting cell-cycle control and apoptosis. This allows accumulation of mutations and malignant transformation.

  41. Question 41Cancer Prevention, Detection, and Diagnosis

    For an average-risk woman with no history of abnormal cytology, cervical cancer screening with cervical cytology should begin at what age?

    1. 21 years Correct answer.
    2. 18 years
    3. 25 years
    4. 30 years

    Explanation

    Cytology-based cervical cancer screening begins at age 21 regardless of age at first intercourse or HPV vaccination status. Women aged 21 to 29 are screened every 3 years, and those 30 and older may switch to co-testing or primary HPV testing. Screening before 21 is discouraged because cervical cancer is rare and transient HPV infections are common at younger ages.

  42. Question 42Cancer Prevention, Detection, and Diagnosis

    At what age does the U.S. Preventive Services Task Force recommend beginning colorectal cancer screening for average-risk adults?

    1. 50 years
    2. 55 years
    3. 45 years Correct answer.
    4. 40 years

    Explanation

    Average-risk colorectal cancer screening now begins at age 45, a change made because incidence in adults younger than 50 has been rising. Screening continues through age 75, with individualized decisions from 76 to 85. Earlier onset screening for higher-risk groups is driven by family history or hereditary syndromes.

  43. Question 43Cancer Prevention, Detection, and Diagnosis

    A 62-year-old current smoker is being evaluated for lung cancer screening with low-dose CT. What is the minimum cumulative tobacco exposure required to meet eligibility criteria?

    1. 20 pack-years Correct answer.
    2. 10 pack-years
    3. 30 pack-years
    4. 15 pack-years

    Explanation

    Eligibility for annual low-dose CT screening requires age 50 to 80, at least 20 pack-years of smoking, and current smoking or quitting within the past 15 years. Pack-years are calculated by multiplying packs smoked per day by years smoked. Patients who quit more than 15 years ago no longer meet criteria.

  44. Question 44Cancer Prevention, Detection, and Diagnosis

    At what age is routine HPV vaccination recommended for adolescents in the United States?

    1. 9 to 10 years
    2. 13 to 14 years
    3. 11 to 12 years Correct answer.
    4. 15 to 16 years

    Explanation

    Routine HPV vaccination is recommended at ages 11 to 12, with catch-up vaccination recommended through age 26. Vaccination may begin at age 9, and two doses are sufficient when the series starts before age 15. The vaccine prevents infections with the HPV types most strongly linked to cervical and oropharyngeal cancers.

  45. Question 45Cancer Prevention, Detection, and Diagnosis

    Pathogenic variants in BRCA1 and BRCA2 most strongly increase the lifetime risk of which cancer pair?

    1. Pancreatic and thyroid
    2. Lung and renal
    3. Breast and ovarian Correct answer.
    4. Colorectal and gastric

    Explanation

    BRCA1 and BRCA2 pathogenic variants confer markedly elevated lifetime risks of breast and ovarian cancer, along with smaller increases in pancreatic and prostate cancer risk. Risk-reducing salpingo-oophorectomy and enhanced breast surveillance are offered based on the specific gene involved. Genetic testing is offered when personal or family history meets testing criteria.

  46. Question 46Cancer Prevention, Detection, and Diagnosis

    In the TNM staging system, what does the T category describe?

    1. Distant metastasis
    2. Tumor differentiation
    3. Regional nodal spread
    4. Primary tumor extent Correct answer.

    Explanation

    The T category describes the size and local extent of the primary tumor, including invasion into adjacent structures. N describes regional lymph node involvement and M describes distant metastasis. Histologic grade is a separate descriptor and is not part of TNM.

  47. Question 47Cancer Prevention, Detection, and Diagnosis

    Which serum marker is used in the detection and monitoring of prostate cancer?

    1. Prostate-specific antigen Correct answer.
    2. CA 125
    3. Carcinoembryonic antigen
    4. CA 19-9

    Explanation

    Prostate-specific antigen is a serine protease produced by prostate epithelium and is used for screening discussions, treatment monitoring, and recurrence surveillance. Carcinoembryonic antigen is used mainly in colorectal cancer monitoring, CA 19-9 in pancreatic cancer, and CA 125 in ovarian cancer. Tumor markers support but do not replace tissue diagnosis.

  48. Question 48Cancer Prevention, Detection, and Diagnosis

    What is the minimum sunscreen sun protection factor generally recommended for reducing skin cancer risk?

    1. 15
    2. 30 Correct answer.
    3. 8
    4. 50

    Explanation

    Broad-spectrum sunscreen with an SPF of at least 30 is recommended, applied generously and reapplied at least every 2 hours during sun exposure. SPF 30 blocks approximately 97% of UVB radiation when applied correctly. Sunscreen should be combined with protective clothing, shade, and avoidance of tanning beds.

  49. Question 49Cancer Prevention, Detection, and Diagnosis

    After a completely normal average-risk screening colonoscopy with adequate bowel preparation and cecal intubation, when should the next colonoscopy be scheduled?

    1. 3 years
    2. 5 years
    3. 15 years
    4. 10 years Correct answer.

    Explanation

    A normal average-risk screening colonoscopy with high-quality preparation and complete intubation warrants a 10-year interval. Shorter intervals are used when adenomas are found, preparation is inadequate, or cecal intubation is not achieved. Documenting bowel preparation quality is essential because it determines whether a full interval can be applied.

  50. Question 50Cancer Prevention, Detection, and Diagnosis

    For a 40-year-old woman with a normal Pap and negative HPV co-test, what is the recommended interval to the next cervical cancer screening?

    1. Every 2 years
    2. Every 5 years Correct answer.
    3. Annually
    4. Every 3 years

    Explanation

    Co-testing with cytology plus HPV testing is performed every 5 years for women aged 30 to 65 when results are normal. This interval reflects the high negative predictive value of concurrent negative cytology and negative high-risk HPV testing. Annual screening is no longer recommended in any average-risk group.

  51. Question 51Cancer Prevention, Detection, and Diagnosis

    For a 45-year-old woman at average risk, which breast cancer screening schedule is consistent with current U.S. Preventive Services Task Force recommendations?

    1. Every 2 years from 40 to 74 Correct answer.
    2. Every 2 years from 50 to 74
    3. Annually from 45 to 54
    4. Annually from age 30

    Explanation

    The USPSTF recommends biennial screening mammography for women aged 40 to 74 years. The updated recommendation lowered the starting age because of rising incidence in younger women. Screening beyond 74 should be individualized based on comorbidity and patient preference.

  52. Question 52Cancer Prevention, Detection, and Diagnosis

    Which test is recommended for all newly diagnosed colorectal cancers to screen for Lynch syndrome?

    1. KRAS testing
    2. APC sequencing
    3. MMR immunohistochemistry Correct answer.
    4. Serum CEA

    Explanation

    Universal screening of all colorectal cancers with mismatch repair immunohistochemistry or microsatellite instability testing identifies patients who should be referred for germline Lynch syndrome evaluation. This approach detects carriers who would be missed by age- or family-history-based criteria alone. APC sequencing is used for familial adenomatous polyposis, and KRAS testing guides therapy rather than inheritance assessment.

  53. Question 53Cancer Prevention, Detection, and Diagnosis

    Why is CA 125 not recommended as a screening test for ovarian cancer in the general population?

    1. It is elevated only in BRCA carriers
    2. It cannot be measured in serum
    3. It is elevated only in late-stage disease
    4. It lacks sufficient sensitivity and specificity Correct answer.

    Explanation

    CA 125 is frequently elevated by benign conditions such as endometriosis, fibroids, and inflammation, and it is often normal in early-stage ovarian cancer, so it fails as a population screening tool. Large trials of combined CA 125 and ultrasound screening did not reduce ovarian cancer mortality. It remains useful for monitoring known disease and treatment response.

  54. Question 54Cancer Prevention, Detection, and Diagnosis

    A patient with compensated hepatitis C cirrhosis is enrolled in hepatocellular carcinoma surveillance. Which schedule is recommended?

    1. AFP alone every 12 months
    2. Ultrasound with or without AFP every 6 months Correct answer.
    3. CT abdomen every 12 months
    4. MRI abdomen every 3 months

    Explanation

    Guidelines recommend surveillance with abdominal ultrasound, with or without alpha-fetoprotein, every 6 months in patients with cirrhosis. Six-month intervals align with tumor doubling time and improve detection of curable disease. AFP alone is not recommended because of limited sensitivity and specificity, though it is often added to ultrasound.

  55. Question 55Cancer Prevention, Detection, and Diagnosis

    What is the purpose of sentinel lymph node biopsy in newly diagnosed breast cancer or melanoma?

    1. To determine histologic grade
    2. To remove all regional lymph nodes
    3. To identify and biopsy the first draining node Correct answer.
    4. To detect distant metastases

    Explanation

    Sentinel lymph node biopsy identifies the first node or nodes draining the tumor and samples them to stage the regional basin while sparing unnecessary complete dissection. A negative sentinel node generally avoids the morbidity of full axillary or inguinal dissection. Grade, in contrast, is determined from the primary tumor specimen.

  56. Question 56Cancer Prevention, Detection, and Diagnosis

    A woman has a suspicious breast mass, and the clinician needs tissue architecture and histologic grade before planning neoadjuvant therapy. Which sampling method is most appropriate?

    1. Bone marrow biopsy
    2. Fine-needle aspiration
    3. Core needle biopsy Correct answer.
    4. Sentinel node biopsy

    Explanation

    Core needle biopsy yields intact tissue architecture, allowing histologic typing, grading, and biomarker testing such as estrogen receptor and HER2 status. Fine-needle aspiration provides cytology only and cannot reliably assess invasion or grade. Surgical excision is reserved for cases in which core biopsy is nondiagnostic.

  57. Question 57Cancer Prevention, Detection, and Diagnosis

    Eradication of Helicobacter pylori is most clearly associated with reduced incidence of which malignancy?

    1. Gastric adenocarcinoma Correct answer.
    2. Pancreatic adenocarcinoma
    3. Esophageal adenocarcinoma
    4. Hepatocellular carcinoma

    Explanation

    Chronic H. pylori infection causes atrophic gastritis and intestinal metaplasia, and eradication reduces the risk of subsequent gastric adenocarcinoma. Eradication is particularly beneficial before severe precancerous changes develop. Esophageal adenocarcinoma is linked to Barrett esophagus and reflux rather than H. pylori.

  58. Question 58Cancer Prevention, Detection, and Diagnosis

    Which serologic marker indicates current hepatitis B virus infection rather than resolved or vaccinated status?

    1. Anti-HBc IgG
    2. Anti-HBe
    3. Anti-HBs
    4. HBsAg Correct answer.

    Explanation

    Hepatitis B surface antigen indicates current infection, whether acute or chronic, and its persistence beyond 6 months defines chronic hepatitis B. Anti-HBs indicates immunity from vaccination or resolved infection, and anti-HBc IgG indicates past exposure. Screening for chronic hepatitis B enables surveillance for hepatocellular carcinoma and antiviral treatment.

  59. Question 59Cancer Prevention, Detection, and Diagnosis

    A 52-year-old average-risk patient declines colonoscopy. Which screening option is appropriate to offer?

    1. CT colonography every 10 years
    2. Annual serum CEA
    3. FIT every 3 years
    4. Annual FIT Correct answer.

    Explanation

    Annual fecal immunochemical testing is an accepted noninvasive option for average-risk colorectal cancer screening, with colonoscopy reserved for positive results. CT colonography is offered every 5 years, not every 10. Serum CEA has no role in screening because it lacks sensitivity for early disease.

  60. Question 60Cancer Prevention, Detection, and Diagnosis

    For a 60-year-old man with no symptoms and no family history of prostate cancer, what is the recommended approach to PSA screening?

    1. Begin at 40 for all men
    2. Screen all men annually from 50
    3. Individualized decision from 55 to 69 Correct answer.
    4. No screening at any age

    Explanation

    The USPSTF recommends individualized shared decision-making about PSA screening for men aged 55 to 69, weighing a small mortality benefit against harms such as overdiagnosis and treatment-related morbidity. Screening is not recommended for men 70 and older. The discussion should incorporate patient values and life expectancy.

  61. Question 61Cancer Prevention, Detection, and Diagnosis

    A patient with a known TP53 pathogenic variant is newly diagnosed with operable breast cancer. Which local treatment approach is generally preferred?

    1. Breast-conserving surgery with radiation
    2. Bilateral prophylactic mastectomy only
    3. Mastectomy to avoid therapeutic radiation Correct answer.
    4. Tamoxifen chemoprevention alone

    Explanation

    In Li-Fraumeni syndrome, therapeutic radiation is avoided when reasonable because of markedly increased risk of radiation-induced second malignancies, so mastectomy is generally preferred over breast-conserving surgery plus radiation. Contralateral risk-reducing mastectomy is often discussed but does not replace treatment of the existing cancer. Chemoprevention alone is not a treatment for established malignancy.

  62. Question 62Cancer Prevention, Detection, and Diagnosis

    A 32-year-old BRCA1 carrier has completed childbearing. At what age is risk-reducing salpingo-oophorectomy generally recommended?

    1. 35 to 40 years Correct answer.
    2. 25 to 30 years
    3. 50 to 55 years
    4. 30 to 35 years

    Explanation

    Risk-reducing salpingo-oophorectomy is typically recommended at ages 35 to 40 for BRCA1 carriers and 40 to 45 for BRCA2 carriers, reflecting the earlier onset of ovarian cancer in BRCA1. Surgery before the recommended window may be considered after childbearing is complete based on family history. Salpingectomy alone is not yet standard risk reduction outside research settings.

  63. Question 63Cancer Prevention, Detection, and Diagnosis

    A patient is found to carry a BRCA variant of uncertain significance. What is the appropriate management?

    1. Standard screening guided by family history Correct answer.
    2. Bilateral mastectomy
    3. Risk-reducing salpingo-oophorectomy
    4. Annual breast MRI only

    Explanation

    A variant of uncertain significance has no established pathogenicity and should not be used to make surgical or enhanced surveillance decisions. Management is based on the patient's personal and family history, the same as for someone without a known pathogenic variant. Reclassification may occur over time, so periodic reassessment is reasonable.

  64. Question 64Cancer Prevention, Detection, and Diagnosis

    A 58-year-old man has nondysplastic Barrett esophagus confirmed on two endoscopies. What surveillance interval is recommended?

    1. Every 3 to 5 years Correct answer.
    2. Every 6 months
    3. Every 6 months to 1 year
    4. Every 5 years

    Explanation

    Nondysplastic Barrett esophagus is surveyed with endoscopy approximately every 3 to 5 years. Intervals shorten to 6 to 12 months when low-grade dysplasia is present and to 3 months for high-grade dysplasia or endoscopic eradication therapy. Surveillance intensity is stratified by the grade of dysplasia.

  65. Question 65Cancer Prevention, Detection, and Diagnosis

    Which statement accurately describes circulating tumor DNA testing in early-stage solid tumors?

    1. It detects only germline variants
    2. It replaces tissue biopsy for diagnosis
    3. Sensitivity is low in early-stage disease Correct answer.
    4. It is approved for population screening

    Explanation

    Circulating tumor DNA assays have limited sensitivity in early-stage and low-tumor-burden disease, so a negative result does not exclude cancer and cannot substitute for tissue diagnosis. Their established roles include genotyping when tissue is insufficient and detecting minimal residual disease in selected cancers. Germline variants are detected through germline testing, not ctDNA assays.

  66. Question 66Cancer Prevention, Detection, and Diagnosis

    For an average-risk adult with no family history, at what age should colorectal cancer screening begin?

    1. 50 years
    2. 55 years
    3. 40 years
    4. 45 years Correct answer.

    Explanation

    Current U.S. guidance recommends starting colorectal cancer screening at age 45 for average-risk adults. Screening may begin earlier when there is a family history or a hereditary syndrome.

  67. Question 67Cancer Prevention, Detection, and Diagnosis

    Which finding on skin examination is most concerning for melanoma?

    1. A symmetric lesion with regular borders
    2. A 3 mm uniformly tan macule
    3. A lesion with asymmetric shape and irregular border Correct answer.
    4. A flesh-colored papule that has been stable for years

    Explanation

    The ABCDE criteria for melanoma include asymmetry, border irregularity, color variation, diameter greater than 6 mm, and evolution over time. A lesion with asymmetry and an irregular border has two concerning features.

  68. Question 68Cancer Prevention, Detection, and Diagnosis

    Which intervention most directly reduces hepatocellular carcinoma incidence in populations with endemic hepatitis B?

    1. Metformin therapy
    2. Routine aspirin chemoprevention
    3. Widespread statin use
    4. Hepatitis B vaccination Correct answer.

    Explanation

    Chronic hepatitis B infection is a major cause of hepatocellular carcinoma, and hepatitis B vaccination prevents chronic infection. Vaccination programs have been associated with reduced hepatocellular carcinoma incidence in endemic areas.

  69. Question 69Cancer Prevention, Detection, and Diagnosis

    A 58-year-old man with a 25 pack-year smoking history who currently smokes asks about lung cancer screening. He has no symptoms. According to the U.S. Preventive Services Task Force, which statement is correct?

    1. He is ineligible because he still smokes.
    2. He is eligible only if he has a 30 pack-year history.
    3. He is eligible for annual low-dose CT screening. Correct answer.
    4. He is not eligible until age 65.

    Explanation

    The USPSTF recommends annual low-dose CT screening for adults aged 50 to 80 years with at least a 20 pack-year smoking history who currently smoke or quit within the past 15 years. This patient meets the age, pack-year, and current smoking criteria.

  70. Question 70Cancer Prevention, Detection, and Diagnosis

    A 20-year-old man is diagnosed with familial adenomatous polyposis after genetic testing. At what age should surveillance colonoscopy have begun?

    1. At age 18
    2. At age 25
    3. At age 40
    4. At age 10 to 12 Correct answer.

    Explanation

    Patients with familial adenomatous polyposis are at very high risk for early colorectal polyps and cancer. Colonoscopy surveillance is recommended beginning at approximately age 10 to 12 years.

  71. Question 71Cancer Prevention, Detection, and Diagnosis

    A 45-year-old woman has a screening mammogram showing a probably benign finding categorized as BI-RADS 3. What is the recommended next step?

    1. Obtain short-interval follow-up imaging in about 6 months Correct answer.
    2. Proceed to bilateral breast MRI
    3. Return for routine screening mammography in 1 year
    4. Perform immediate core needle biopsy

    Explanation

    A BI-RADS 3 lesion is considered probably benign, and the standard recommendation is short-interval follow-up imaging, usually at about 6 months. Immediate biopsy is reserved for more suspicious findings.

  72. Question 72Cancer Prevention, Detection, and Diagnosis

    Which symptom pattern should prompt evaluation for possible ovarian cancer?

    1. Cyclic pelvic pain that occurs with each menstrual period
    2. Persistent bloating and early satiety lasting several weeks Correct answer.
    3. Sudden sharp pelvic pain after strenuous exercise
    4. Acute fever with dysuria and flank pain

    Explanation

    Ovarian cancer often presents with persistent bloating, early satiety, pelvic or abdominal pain, and urinary urgency. Symptoms that are new and persist for several weeks warrant evaluation.

  73. Question 73Cancer Prevention, Detection, and Diagnosis

    A 68-year-old man with no family history presents with new-onset diabetes and unintentional weight loss. What is the most appropriate next step?

    1. Repeat hemoglobin A1c in 1 year
    2. Start insulin and defer further evaluation
    3. Evaluate for pancreatic cancer with abdominal imaging Correct answer.
    4. Reassure him that new diabetes is expected with aging

    Explanation

    New-onset diabetes in an older adult, especially when accompanied by weight loss, can be an early sign of pancreatic cancer. Imaging should be considered to evaluate for an underlying malignancy.

  74. Question 74Cancer Prevention, Detection, and Diagnosis

    Which statement about carcinoembryonic antigen (CEA) in colorectal cancer is accurate?

    1. An elevated level confirms a diagnosis of colorectal cancer.
    2. It is the preferred test for identifying Lynch syndrome.
    3. It is recommended as a primary screening test for average-risk adults.
    4. It is useful for monitoring for recurrence after curative treatment. Correct answer.

    Explanation

    CEA is not sensitive or specific enough for colorectal cancer screening or diagnosis. Its main role is serial monitoring after curative treatment, when rising levels can suggest recurrence.

  75. Question 75Cancer Prevention, Detection, and Diagnosis

    A 40-year-old woman has a 1.6 cm solid hypoechoic thyroid nodule with microcalcifications. Her TSH is normal. What is the next step?

    1. Empiric TSH suppression with levothyroxine
    2. Radionuclide thyroid scan
    3. Fine-needle aspiration biopsy Correct answer.
    4. Repeat ultrasound in 12 months

    Explanation

    A solid hypoechoic nodule with microcalcifications has suspicious ultrasound features. Fine-needle aspiration is recommended for suspicious nodules that are at least 1 cm in largest dimension.

  76. Question 76Cancer Prevention, Detection, and Diagnosis

    A patient with multiple endocrine neoplasia type 2A and a RET codon 634 mutation is identified. Which management is recommended?

    1. Levothyroxine suppression of TSH
    2. Prophylactic thyroidectomy in early childhood Correct answer.
    3. Annual calcitonin monitoring alone
    4. External beam radiation to the thyroid

    Explanation

    RET mutations in MEN2 confer a high risk of medullary thyroid carcinoma. Prophylactic thyroidectomy is recommended at an early age, with timing guided by the specific RET mutation.

  77. Question 77Cancer Prevention, Detection, and Diagnosis

    A patient with Lynch syndrome asks about chemoprevention for colorectal cancer. Which intervention has the best evidence for reducing colorectal cancer incidence?

    1. Metformin therapy
    2. Daily calcium supplementation
    3. Statin therapy
    4. Daily aspirin Correct answer.

    Explanation

    Randomized trial evidence in Lynch syndrome suggests that daily aspirin reduces colorectal cancer incidence. Calcium, statins, and metformin are not established chemopreventive agents for this population.

  78. Question 78Cancer Prevention, Detection, and Diagnosis

    A 35-year-old patient has a CDH1 pathogenic variant and a family history of diffuse gastric cancer. Which management is recommended?

    1. Annual upper endoscopy with random biopsies only
    2. Prophylactic total gastrectomy Correct answer.
    3. Helicobacter pylori eradication alone
    4. Surveillance every 5 years with CT imaging

    Explanation

    CDH1 pathogenic variants cause hereditary diffuse gastric cancer, and prophylactic total gastrectomy is recommended because endoscopic surveillance is insensitive for this cancer type. Management should occur at a specialized center.

  79. Question 79Cancer Prevention, Detection, and Diagnosis

    A prostate biopsy reports Gleason score 4+3=7. Which Grade Group does this correspond to?

    1. Grade Group 1
    2. Grade Group 5
    3. Grade Group 2
    4. Grade Group 3 Correct answer.

    Explanation

    Grade Group 1 corresponds to Gleason score 6 or less, Grade Group 2 to 3+4=7, and Grade Group 3 to 4+3=7. Grade Group 4 is Gleason score 8, and Grade Group 5 is Gleason score 9 to 10.

  80. Question 80Cancer Prevention, Detection, and Diagnosis

    A 66-year-old woman with no history of cervical intraepithelial neoplasia grade 2 or worse has records showing three consecutive negative cervical cytology results within the past 10 years, with the most recent test performed 2 years ago. She is asymptomatic. What is the most appropriate recommendation?

    1. Continue cytology plus HPV co-testing every 5 years until age 75
    2. Continue annual cytology alone indefinitely
    3. Discontinue cervical cancer screening Correct answer.
    4. Refer for colposcopy before any decision to stop screening

    Explanation

    Cervical cancer screening can be discontinued at age 65 when there is documented adequate prior negative screening (three consecutive negative cytology results or two consecutive negative co-tests within the prior 10 years, with the most recent test within the recommended interval) and no history of CIN 2 or worse. This patient meets those criteria, so no further routine screening is indicated. Continued screening past age 65 is reserved for patients who lack adequate prior negative results or have a history of high-grade dysplasia.

  81. Question 81Cancer Treatment Modalities

    Which statement best explains why external beam radiation is delivered in multiple small fractions rather than as one large dose?

    1. It prevents tumor cells from developing resistance to ionizing radiation over time.
    2. Normal tissues repair sublethal damage between doses more effectively than tumors. Correct answer.
    3. It eliminates the need for daily image guidance and immobilization during treatment.
    4. It permits a higher total dose to be delivered in one session than fractionation allows.

    Explanation

    Fractionation exploits the difference in sublethal DNA damage repair between normal tissue and tumor; normal cells recover between fractions while tumor cells accumulate injury. Smaller fractions also allow reoxygenation and reassortment of cells into more radiosensitive cell-cycle phases. The total dose is actually split across many sessions, not concentrated into one.

  82. Question 82Cancer Treatment Modalities

    A patient with localized prostate cancer is scheduled for brachytherapy. Which description accurately characterizes this treatment modality?

    1. A radiolabeled monoclonal antibody is infused and binds systemically to tumor cells.
    2. Oral radioactive iodine is given and concentrates selectively in tumor tissue.
    3. High-energy photon beams are directed at the tumor from several external angles.
    4. A sealed source placed in or near the tumor delivers a highly localized dose. Correct answer.

    Explanation

    Brachytherapy uses a sealed radioactive source implanted within or adjacent to the tumor, producing a very high local dose with a steep dose gradient that spares nearby normal structures. It differs from external beam therapy, which delivers radiation from outside the body. Systemic radionuclide therapies rely on tumor-specific uptake rather than implantation.

  83. Question 83Cancer Treatment Modalities

    Which chemotherapy agent is classified as cell-cycle phase specific and exerts its principal effect during the S phase?

    1. Methotrexate Correct answer.
    2. Vincristine
    3. Cyclophosphamide
    4. Cisplatin

    Explanation

    Methotrexate inhibits dihydrofolate reductase and thereby DNA synthesis, so its cytotoxicity is greatest during the S phase. Vincristine is also cell-cycle specific but arrests cells in mitosis. Alkylating agents such as cyclophosphamide and platinum compounds such as cisplatin are cell-cycle nonspecific.

  84. Question 84Cancer Treatment Modalities

    During an infusion of intravenous doxorubicin through a peripheral IV, the patient reports burning and the site becomes erythematous and swollen. Which agent is the specific antidote for anthracycline extravasation?

    1. Hyaluronidase
    2. Dimethyl sulfoxide
    3. Sodium thiosulfate
    4. Dexrazoxane Correct answer.

    Explanation

    Dexrazoxane is approved as a specific antidote for anthracycline extravasation and should be given as soon as extravasation is suspected, following the recommended dosing schedule. Sodium thiosulfate is used for mechlorethamine extravasation and hyaluronidase for vinca alkaloid and taxane extravasation. Prompt cessation of the infusion and cold compresses are also part of initial management.

  85. Question 85Cancer Treatment Modalities

    A patient with Burkitt lymphoma and a high white blood cell count is at high risk for tumor lysis syndrome. Which medication most rapidly lowers an already elevated serum uric acid level?

    1. Allopurinol
    2. Sodium bicarbonate
    3. Febuxostat
    4. Rasburicase Correct answer.

    Explanation

    Rasburicase is a recombinant urate oxidase that converts existing uric acid to the highly soluble allantoin, producing a rapid decline in serum uric acid. Allopurinol and febuxostat inhibit xanthine oxidase and prevent formation of new uric acid but do not degrade uric acid already present. Rasburicase is contraindicated in glucose-6-phosphate dehydrogenase deficiency.

  86. Question 86Cancer Treatment Modalities

    Which immune checkpoint inhibitor works by blocking CTLA-4?

    1. Pembrolizumab
    2. Ipilimumab Correct answer.
    3. Atezolizumab
    4. Nivolumab

    Explanation

    Ipilimumab is a fully human monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal during T-cell priming. Pembrolizumab and nivolumab block PD-1, and atezolizumab blocks PD-L1. These distinctions matter because toxicity profiles and monitoring differ somewhat between CTLA-4 and PD-1/PD-L1 blockade.

  87. Question 87Cancer Treatment Modalities

    A patient receiving pembrolizumab develops grade 3 diarrhea, and colonoscopy with biopsy confirms immune-mediated colitis. What is the most appropriate initial management?

    1. Switch to nivolumab and add prophylactic antibiotics.
    2. Hold pembrolizumab and start high-dose systemic corticosteroids. Correct answer.
    3. Continue therapy and obtain serial stool cultures while observing.
    4. Continue pembrolizumab and start loperamide for symptom control.

    Explanation

    Grade 3 immune-mediated colitis requires holding the checkpoint inhibitor and initiating high-dose corticosteroids, typically 1 to 2 mg/kg/day of prednisone equivalent. Infliximab is reserved for steroid-refractory cases. Continuing the drug or simply controlling symptoms risks progression to perforation or toxic megacolon.

  88. Question 88Cancer Treatment Modalities

    A patient develops grade 2 cytokine release syndrome 3 days after chimeric antigen receptor T-cell infusion. Which agent is the standard first-line treatment?

    1. High-dose cyclophosphamide
    2. Tocilizumab Correct answer.
    3. Corticosteroids alone
    4. Infliximab

    Explanation

    Tocilizumab, an anti-interleukin-6 receptor antibody, is the first-line therapy for grade 2 or higher cytokine release syndrome after CAR-T therapy. Corticosteroids are added for grade 3 or higher disease or for toxicity that does not respond to tocilizumab. Infliximab is used for immune effector cell-associated neurotoxicity or colitis, not as initial CRS therapy.

  89. Question 89Cancer Treatment Modalities

    Which targeted agent requires baseline and periodic assessment of left ventricular ejection fraction because of a risk of cardiomyopathy?

    1. Trastuzumab Correct answer.
    2. Cetuximab
    3. Bevacizumab
    4. Rituximab

    Explanation

    Trastuzumab, a HER2-directed antibody, is associated with a reversible decline in left ventricular ejection fraction, and risk increases with concurrent or prior anthracyclines. Guideline practice is to check ejection fraction at baseline and at regular intervals during therapy. Rituximab and cetuximab do not carry this monitoring requirement.

  90. Question 90Cancer Treatment Modalities

    Imatinib is the targeted treatment of choice for chronic myeloid leukemia because it inhibits which target?

    1. The EGFR tyrosine kinase domain
    2. The BCR-ABL fusion kinase Correct answer.
    3. The ALK receptor tyrosine kinase
    4. The BRAF V600E kinase

    Explanation

    Imatinib inhibits the BCR-ABL fusion tyrosine kinase created by the Philadelphia chromosome, which drives chronic myeloid leukemia. This was one of the first successes of molecularly targeted therapy. EGFR, ALK, and BRAF inhibitors are used in other tumor types defined by those alterations.

  91. Question 91Cancer Treatment Modalities

    A 55-year-old woman taking tamoxifen for breast cancer reports new irregular vaginal bleeding. What is the most appropriate next step?

    1. Perform an endometrial evaluation with biopsy. Correct answer.
    2. Obtain a serum CA-125 level and repeat it in 3 months.
    3. Stop tamoxifen immediately and switch to an aromatase inhibitor.
    4. Reassure her that irregular bleeding is expected on tamoxifen.

    Explanation

    Tamoxifen has partial estrogen agonist activity on the endometrium and increases the risk of endometrial hyperplasia and carcinoma, so any abnormal bleeding requires prompt endometrial evaluation with biopsy. Bleeding is not a benign expected effect that can be managed by reassurance. Therapy is not changed before the source of bleeding is defined.

  92. Question 92Cancer Treatment Modalities

    Which adverse effect is most characteristic of aromatase inhibitors in postmenopausal women with breast cancer?

    1. Accelerated bone loss with arthralgias Correct answer.
    2. Endometrial hyperplasia and vaginal bleeding
    3. Alopecia and peripheral neuropathy
    4. Venous thromboembolism and hot flashes

    Explanation

    By suppressing residual estrogen production, aromatase inhibitors accelerate bone mineral loss and cause arthralgias and myalgias, so baseline and serial bone density assessment is recommended. Endometrial hyperplasia and venous thromboembolism are associated with tamoxifen rather than aromatase inhibitors. Alopecia and neuropathy are chemotherapy effects.

  93. Question 93Cancer Treatment Modalities

    What is the primary purpose of sentinel lymph node biopsy in a patient with clinically node-negative breast cancer?

    1. To remove all axillary lymph nodes as definitive regional therapy
    2. To find and biopsy the first draining node to stage the axilla Correct answer.
    3. To determine the estrogen receptor status of the primary tumor
    4. To assess bone marrow involvement by tumor

    Explanation

    The sentinel node is the first node to receive lymphatic drainage from the tumor; identifying and biopsying it allows accurate axillary staging while sparing most patients the morbidity of a full axillary dissection. Complete axillary dissection is reserved for proven nodal disease or specific indications. Receptor status and marrow involvement are determined by other tests.

  94. Question 94Cancer Treatment Modalities

    What is a primary goal of neoadjuvant chemotherapy in locally advanced breast cancer?

    1. It shrinks the tumor enough to permit breast-conserving surgery. Correct answer.
    2. It reduces systemic toxicity compared with adjuvant chemotherapy.
    3. It confirms the histologic diagnosis before surgery.
    4. It eliminates the need for surgical resection in most patients.

    Explanation

    Neoadjuvant chemotherapy is given before surgery chiefly to downstage the primary tumor so that breast conservation becomes feasible and, in some subtypes, to guide postoperative therapy based on response. Surgery is still required afterward. Diagnosis is established by biopsy before treatment, and toxicity is not inherently lower than with adjuvant delivery.

  95. Question 95Cancer Treatment Modalities

    Which statement accurately describes a key immunologic difference between autologous and allogeneic hematopoietic stem cell transplant?

    1. Autologous transplant provides a graft-versus-tumor effect from donor cells.
    2. Allogeneic transplant can produce a graft-versus-tumor effect. Correct answer.
    3. Allogeneic transplant does not require a conditioning regimen.
    4. Autologous transplant carries a substantial risk of graft-versus-host disease.

    Explanation

    In an allogeneic transplant, donor T cells recognize host tumor cells as foreign and mediate a graft-versus-tumor effect, which contributes to lower relapse rates in some diseases. Autologous grafts use the patient's own cells and produce no such allogeneic effect. Graft-versus-host disease is a complication unique to allogeneic transplantation, and allogeneic recipients always receive some form of conditioning.

  96. Question 96Cancer Treatment Modalities

    A patient develops jaundice, tender hepatomegaly, and rapid weight gain with ascites three weeks after allogeneic stem cell transplant. Which diagnosis is most likely?

    1. Sinusoidal obstruction syndrome Correct answer.
    2. Hepatic candidiasis with microabscesses
    3. Acute hepatic graft-versus-host disease
    4. Acute cholecystitis with choledocholithiasis

    Explanation

    The triad of jaundice, painful hepatomegaly, and fluid retention with weight gain in the early post-transplant period is characteristic of sinusoidal obstruction syndrome, formerly called veno-occlusive disease. It results from conditioning-related endothelial injury in hepatic sinusoids. Hepatic graft-versus-host disease causes jaundice but typically without tender hepatomegaly or rapid fluid accumulation.

  97. Question 97Cancer Treatment Modalities

    A phase I clinical trial is primarily designed to determine which of the following?

    1. The maximum tolerated dose and dose-limiting toxicities Correct answer.
    2. The cost-effectiveness of the new regimen compared with usual care
    3. Whether the agent improves overall survival versus standard therapy
    4. The prevalence of the target mutation in the general population

    Explanation

    Phase I trials establish the safety profile, dose-limiting toxicities, and maximum tolerated or recommended phase II dose of a new agent, often using dose escalation in a small cohort. Comparison of survival against standard therapy is the domain of phase III trials. Cost-effectiveness and population mutation prevalence are addressed by other types of research.

  98. Question 98Cancer Treatment Modalities

    Which regimen represents appropriate prophylaxis before a highly emetogenic chemotherapy regimen such as cisplatin?

    1. Metoclopramide plus diphenhydramine before and after treatment
    2. Lorazepam alone given the night before treatment
    3. Prochlorperazine as needed after the infusion
    4. An NK1 antagonist, a 5-HT3 antagonist, and dexamethasone Correct answer.

    Explanation

    Guidelines recommend a three-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone for highly emetogenic regimens, with olanzapine frequently added. Prophylaxis must be given before chemotherapy rather than reserving antiemetics for breakthrough symptoms. Dopamine antagonists and lorazepam are adjuncts for breakthrough or anticipatory nausea.

  99. Question 99Cancer Treatment Modalities

    A patient receiving myelosuppressive chemotherapy has an absolute neutrophil count of 300 cells/µL and a temperature of 38.5°C. What is the most appropriate immediate action?

    1. Give acetaminophen and reassess in 4 hours.
    2. Start empiric broad-spectrum antibiotics within 1 hour. Correct answer.
    3. Administer colony-stimulating factor and reassess in 24 hours.
    4. Obtain blood cultures and withhold antibiotics until results return.

    Explanation

    Febrile neutropenia is an oncologic emergency; empiric broad-spectrum bactericidal antibiotics must be started within about one hour of presentation, after cultures are drawn but without waiting for results. Delays increase the risk of septic shock and death. Antipyretics alone mask the fever, and growth factors are not a substitute for antibiotics.

  100. Question 100Cancer Treatment Modalities

    Which adverse effect is most characteristic of bevacizumab therapy?

    1. Hypertension and poor wound healing Correct answer.
    2. Acneiform rash with chronic diarrhea
    3. Hypothyroidism and fatigue
    4. QT interval prolongation

    Explanation

    Bevacizumab binds vascular endothelial growth factor, and its characteristic toxicities include hypertension, proteinuria, impaired wound healing, bleeding, arterial thromboembolism, and gastrointestinal perforation. Blood pressure should be monitored throughout therapy, and elective surgery requires a treatment-free interval. Acneiform rash is typical of EGFR inhibitors, and QT prolongation is associated with certain other kinase inhibitors.

  101. Question 101Cancer Treatment Modalities

    Which treatment modality is standard adjuvant therapy after total thyroidectomy for differentiated thyroid cancer with significant residual risk?

    1. Radioactive iodine-131 ablation Correct answer.
    2. Interstitial brachytherapy to the thyroid bed
    3. External beam radiation to the neck
    4. Systemic cytotoxic chemotherapy

    Explanation

    Differentiated thyroid cancer cells retain the capacity to take up iodine, so radioiodine-131 is used after total thyroidectomy to ablate residual thyroid tissue and treat microscopic disease. External beam radiation is reserved for selected unresectable or radioiodine-refractory disease. Cytotoxic chemotherapy has little role in differentiated thyroid cancer.

  102. Question 102Cancer Treatment Modalities

    Why is leucovorin administered after high-dose methotrexate?

    1. To bypass the blocked dihydrofolate reductase step in normal cells Correct answer.
    2. To inhibit dihydrofolate reductase and potentiate the antitumor effect
    3. To bind circulating methotrexate and inactivate it in plasma
    4. To alkalinize the urine and enhance renal excretion of methotrexate

    Explanation

    Leucovorin is a reduced folate that enters cells and replenishes tetrahydrofolate pools downstream of the dihydrofolate reductase block, rescuing normal tissues from methotrexate toxicity. Because it is taken up less efficiently by tumor cells, the antitumor effect is largely preserved when timing and dosing are correct. Urine alkalinization is a separate supportive measure.

  103. Question 103Cancer Treatment Modalities

    How do dose density and dose intensity differ in chemotherapy planning?

    1. Both terms describe total cumulative dose and are used interchangeably in practice.
    2. Dose intensity refers to the interval between cycles; dose density refers to dose per cycle.
    3. Dose density shortens cycle intervals; dose intensity is drug amount per unit time. Correct answer.
    4. Dose density increases the dose per cycle; dose intensity shortens the total treatment duration.

    Explanation

    Dose density refers to delivering the planned dose per cycle with shorter intervals between cycles, whereas dose intensity is the amount of drug delivered per unit of time, such as milligrams per square meter per week. Dose-dense regimens increase dose intensity by compressing the schedule without raising the individual dose. The two concepts are related but not interchangeable.

  104. Question 104Cancer Treatment Modalities

    Trastuzumab emtansine is an antibody-drug conjugate. Which payload is linked to the trastuzumab antibody?

    1. A maytansine microtubule inhibitor Correct answer.
    2. A DNA cross-linking alkylator
    3. A therapeutic radionuclide
    4. A topoisomerase I inhibitor (exatecan derivative)

    Explanation

    Trastuzumab emtansine couples trastuzumab to DM1, a maytansine derivative that inhibits microtubule assembly after internalization into HER2-expressing cells. This delivers cytotoxic therapy selectively to antigen-expressing tumor cells. Topoisomerase I inhibitor payloads are used in other conjugates such as trastuzumab deruxtecan.

  105. Question 105Cancer Treatment Modalities

    A patient who completed chest wall radiation three months ago now receives docetaxel and develops an erythematous, sometimes blistering rash confined precisely to the previously irradiated field. What is this phenomenon?

    1. Drug-induced photosensitivity reaction
    2. Radiation recall dermatitis Correct answer.
    3. Acute radiation dermatitis
    4. Cellulitis of the irradiated chest wall

    Explanation

    Radiation recall is an inflammatory reaction precipitated by a systemic agent, often chemotherapy or an immune checkpoint inhibitor, in a previously irradiated area, and it can occur weeks to months or years after radiation. It is confined to the prior radiation port, which distinguishes it from a generalized drug eruption. Management includes topical corticosteroids and holding the offending agent in severe cases.

  106. Question 106Cancer Treatment Modalities

    Rituximab is a chimeric monoclonal antibody used in B-cell lymphomas. Which target does it bind?

    1. CD3 on T lymphocytes
    2. CD20 on B lymphocytes Correct answer.
    3. HER2 on breast epithelial cells
    4. Vascular endothelial growth factor A

    Explanation

    Rituximab binds the CD20 antigen expressed on normal and malignant B cells, producing complement-mediated and antibody-dependent cellular cytotoxicity. CD20 is not expressed on T cells or on most other tissues, which limits off-target injury.

  107. Question 107Cancer Treatment Modalities

    A patient receiving bleomycin as part of a lymphoma regimen reports progressive dyspnea and a dry cough. Which toxicity should be suspected first?

    1. Pulmonary fibrosis Correct answer.
    2. Hemorrhagic cystitis
    3. Sensorineural hearing loss
    4. Dose-related cardiac dysfunction

    Explanation

    Bleomycin causes cumulative, dose-related pneumonitis that can progress to pulmonary fibrosis, typically presenting with dyspnea, dry cough, and basilar infiltrates. Risk rises with cumulative doses above roughly 400 units and with age or thoracic radiation.

  108. Question 108Cancer Treatment Modalities

    Which statement best describes brachytherapy?

    1. High-energy photon beams are directed at the tumor from a machine outside the body
    2. A radiolabeled antibody is infused systemically and binds to tumor cells
    3. A sealed radioactive source is positioned in or next to the tumor Correct answer.
    4. The tumor is treated with a beam that rotates continuously around the patient

    Explanation

    Brachytherapy delivers radiation from a sealed source placed inside a body cavity or implanted directly into tissue, allowing a high dose to the tumor with rapid falloff to surrounding normal structures. Teletherapy, by contrast, delivers radiation from a distance.

  109. Question 109Cancer Treatment Modalities

    A patient is starting a myelosuppressive regimen. When should pegfilgrastim be given?

    1. Only after the ANC falls below 500 cells/µL
    2. On the same day, immediately before the infusion
    3. At least 24 hours after chemotherapy is completed Correct answer.
    4. Two hours before each chemotherapy dose

    Explanation

    Pegfilgrastim is a long-acting granulocyte colony-stimulating factor given once per cycle, no sooner than 24 hours after chemotherapy. Administering it before or at the same time as cytotoxic chemotherapy can stimulate and then deplete dividing myeloid precursors, worsening neutropenia.

  110. Question 110Cancer Treatment Modalities

    A patient with Burkitt lymphoma has a uric acid of 11 mg/dL and is about to begin chemotherapy. Which agent is most appropriate for tumor lysis prophylaxis?

    1. Intravenous sodium bicarbonate alone
    2. Febuxostat
    3. Rasburicase Correct answer.
    4. Allopurinol

    Explanation

    Rasburicase is a urate oxidase that rapidly degrades existing uric acid to allantoin and is preferred when hyperuricemia is already present or risk is high. It is contraindicated in glucose-6-phosphate dehydrogenase deficiency because of the risk of severe hemolysis.

  111. Question 111Cancer Treatment Modalities

    A patient taking capecitabine develops painful erythema and desquamation of the palms and soles. What is the most appropriate initial management?

    1. Continue the same dose and add a topical corticosteroid cream
    2. Add pyridoxine and continue without dose modification
    3. Discontinue capecitabine permanently and switch to a taxane
    4. Hold capecitabine, then resume at a reduced dose Correct answer.

    Explanation

    Hand-foot syndrome is a dose-related toxicity of capecitabine and fluoropyrimidines; painful desquamation warrants interruption followed by dose reduction on recovery, along with supportive skin care. Escalating treatment without dose modification risks progression to blistering and loss of function.

  112. Question 112Cancer Treatment Modalities

    A patient beginning cetuximab for colorectal cancer asks about skin effects. Which skin reaction is most characteristic?

    1. Hyperpigmentation of the oral mucosa
    2. Painful acral erythema with peeling fingertips
    3. A papulopustular eruption on the face and upper trunk Correct answer.
    4. Diffuse urticarial wheals within minutes of infusion

    Explanation

    EGFR inhibitors such as cetuximab and panitumumab produce a papulopustular (acneiform) eruption in a seborrheic distribution, typically within the first weeks of therapy. Management includes topical antibiotics, moisturizers, sunscreen, and sometimes oral doxycycline.

  113. Question 113Cancer Treatment Modalities

    Mesna is coadministered with ifosfamide to prevent which toxicity?

    1. Severe prolonged myelosuppression
    2. Hemorrhagic cystitis caused by acrolein Correct answer.
    3. Dose-limiting central neurotoxicity
    4. Proximal tubular damage from a chloroacetaldehyde metabolite

    Explanation

    Mesna is a thiol compound excreted in urine, where it inactivates acrolein, the urotoxic metabolite of ifosfamide and cyclophosphamide, thereby preventing hemorrhagic cystitis. It does not prevent the nephrotoxicity or neurotoxicity of ifosfamide.

  114. Question 114Cancer Treatment Modalities

    Why is prednisone given together with abiraterone in metastatic prostate cancer?

    1. To prevent an infusion-related hypersensitivity reaction
    2. To reduce the risk of abiraterone-related seizures
    3. To offset mineralocorticoid excess from CYP17 inhibition Correct answer.
    4. To improve conversion of abiraterone to its active form

    Explanation

    Abiraterone inhibits CYP17 and blocks androgen synthesis, which raises ACTH and shunts precursors toward mineralocorticoids, causing hypertension, hypokalemia, and edema. Low-dose prednisone suppresses ACTH and mitigates this syndrome.

  115. Question 115Cancer Treatment Modalities

    Olaparib is effective in BRCA-mutated ovarian cancer because it inhibits which target?

    1. Epidermal growth factor receptor
    2. Vascular endothelial growth factor receptor
    3. Poly (ADP-ribose) polymerase Correct answer.
    4. Mammalian target of rapamycin

    Explanation

    Olaparib inhibits poly (ADP-ribose) polymerase, blocking single-strand break repair; in cells lacking homologous recombination because of BRCA loss, unrepaired breaks collapse replication forks and the cells die. This concept is termed synthetic lethality.

  116. Question 116Cancer Treatment Modalities

    A patient receiving vincristine develops severe constipation and jaw pain. Which statement about vincristine dosing is correct?

    1. Vincristine is dosed by body surface area without an upper limit
    2. Doses above 2 mg are required for adequate antitumor effect
    3. The dose should be escalated until mild neuropathy appears
    4. The single dose is usually capped at 2 mg Correct answer.

    Explanation

    Vincristine neurotoxicity is dose-related, and a single adult dose is conventionally capped at 2 mg to limit peripheral and autonomic neuropathy. Vincristine is also uniformly fatal if given intrathecally, so route verification is essential.

  117. Question 117Cancer Treatment Modalities

    Which agent is used to reduce the duration and severity of oral mucositis in patients receiving high-dose chemotherapy with stem cell rescue?

    1. Palifermin Correct answer.
    2. Amifostine
    3. Leucovorin
    4. Filgrastim

    Explanation

    Palifermin is a recombinant human keratinocyte growth factor given before and after high-dose chemotherapy with or without total body irradiation to stimulate epithelial proliferation and reduce mucositis.

  118. Question 118Cancer Treatment Modalities

    A trial is designed to show that a less toxic regimen is no worse than standard therapy by more than a prespecified margin. Which design does this describe?

    1. A noninferiority trial Correct answer.
    2. A superiority trial with a two-sided alpha of 0.05
    3. A dose-escalation phase I trial
    4. A single-arm phase II trial

    Explanation

    A noninferiority trial tests whether an experimental regimen is not worse than the standard by more than a defined margin, allowing a better-tolerated option to be adopted without demonstrated superiority. Both intention-to-treat and per-protocol analyses are usually reported because each guards against different biases.

  119. Question 119Cancer Treatment Modalities

    A patient with metastatic sarcoma has received doxorubicin 400 mg/m2 and continues to respond. Which strategy best addresses cumulative cardiotoxicity risk?

    1. Switch to high-dose bolus doxorubicin infusions
    2. Add dexrazoxane as a cardioprotectant Correct answer.
    3. Obtain an ECG before each dose and continue the same dose
    4. Add a beta-blocker and continue doxorubicin without modification

    Explanation

    Dexrazoxane is an iron-chelating agent that reduces anthracycline-induced free radical injury to myocardium and is used when cumulative doxorubicin exposure is high but continued therapy is beneficial. Serial assessment of left ventricular function remains part of monitoring.

  120. Question 120Cancer Treatment Modalities

    Cisplatin is given concurrently with radiation for locally advanced cervical cancer primarily because it does what?

    1. Sensitizes tumor cells to radiation and improves local control Correct answer.
    2. Reduces radiation-induced injury to normal pelvic tissue
    3. Shortens the total duration of the radiation course
    4. Prevents distant metastasis through systemic cytotoxicity alone

    Explanation

    Concurrent cisplatin acts as a radiosensitizer, for example by inhibiting repair of radiation-induced DNA damage and synchronizing cells into radiosensitive phases, which improves local control and survival. The schedule is chosen for radiosensitization rather than for dose-intensive systemic therapy.

  121. Question 121Supportive, Palliative, and End-of-Life Care

    A patient with chemotherapy-induced peripheral neuropathy reports burning pain in both feet. Which medication is the most appropriate first-line treatment?

    1. Gabapentin Correct answer.
    2. Acetaminophen
    3. Ibuprofen
    4. Oxycodone

    Explanation

    Gabapentinoids are first-line adjuvants for neuropathic pain because they reduce ectopic nerve firing. NSAIDs and acetaminophen are ineffective for neuropathic pain, and opioids are not preferred as initial monotherapy.

  122. Question 122Supportive, Palliative, and End-of-Life Care

    Ondansetron is used to prevent chemotherapy-induced nausea and vomiting. Which receptor does it block?

    1. Dopamine D2 receptor
    2. Histamine H1 receptor
    3. 5-HT3 receptor Correct answer.
    4. NK1 receptor

    Explanation

    Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin signals in the gut and chemoreceptor trigger zone. This makes it effective for acute chemotherapy-induced emesis.

  123. Question 123Supportive, Palliative, and End-of-Life Care

    Which intervention is recommended for a patient with chemotherapy-induced oral mucositis who can tolerate oral intake?

    1. Routine chlorhexidine mouthwash
    2. Saline or sodium bicarbonate rinses with oral hygiene Correct answer.
    3. Deep airway suctioning every 2 hours
    4. Topical lidocaine before every meal

    Explanation

    Saline or sodium bicarbonate rinses with gentle oral hygiene reduce discomfort and keep the mucosa clean. Chlorhexidine is not recommended, and topical lidocaine before meals can impair the gag reflex.

  124. Question 124Supportive, Palliative, and End-of-Life Care

    Which statement best describes hospice eligibility for a patient with advanced cancer?

    1. The patient must be hospitalized.
    2. A prognosis of 6 months or less if the illness runs its expected course. Correct answer.
    3. The patient must have completed all cancer-directed therapy and achieved remission.
    4. The patient must have a do-not-resuscitate order.

    Explanation

    Hospice eligibility requires a prognosis of 6 months or less if the disease follows its expected course, along with a comfort-focused plan of care. A do-not-resuscitate order is not required, and patients may receive hospice at home.

  125. Question 125Supportive, Palliative, and End-of-Life Care

    A patient with an absolute neutrophil count of 400/µL develops a temperature of 38.5°C. What is the most appropriate next step?

    1. Start oral fluconazole and discharge home
    2. Wait for blood culture results before starting any antibiotic therapy
    3. Administer acetaminophen and reassess in 4 hours
    4. Cultures then empiric broad-spectrum antibiotics within 1 hour Correct answer.

    Explanation

    Febrile neutropenia is an oncologic emergency. Blood cultures should be drawn promptly, followed by empiric antipseudomonal broad-spectrum antibiotics within 60 minutes.

  126. Question 126Supportive, Palliative, and End-of-Life Care

    A patient receiving cisplatin develops nausea 3 days after treatment. Which regimen is most appropriate for delayed chemotherapy-induced nausea and vomiting?

    1. Ondansetron given as a single agent
    2. Aprepitant plus dexamethasone Correct answer.
    3. Metoclopramide given as a single agent
    4. Diphenhydramine given as a single agent

    Explanation

    Delayed emesis after cisplatin is mediated largely by substance P, so an NK1 antagonist such as aprepitant combined with dexamethasone is recommended. 5-HT3 antagonists are less effective in the delayed phase.

  127. Question 127Supportive, Palliative, and End-of-Life Care

    A patient starting long-acting morphine reports no bowel movement for 4 days. Which prophylactic measure is recommended?

    1. Scheduled senna Correct answer.
    2. Oral docusate sodium alone
    3. Prune juice as needed
    4. Increase dietary fiber alone

    Explanation

    Opioids cause constipation through decreased peristalsis and increased sphincter tone, so a scheduled stimulant laxative such as senna is recommended. Docusate alone is ineffective, and fiber can worsen symptoms without adequate fluid intake.

  128. Question 128Supportive, Palliative, and End-of-Life Care

    A patient with ovarian cancer and a malignant bowel obstruction has persistent vomiting. Which medication is most appropriate to reduce gastrointestinal secretions?

    1. Metoclopramide
    2. Octreotide Correct answer.
    3. Ondansetron
    4. Dexamethasone

    Explanation

    Octreotide reduces gastric and intestinal secretions and is used to control vomiting in malignant bowel obstruction. Metoclopramide is contraindicated in complete obstruction because it increases peristalsis.

  129. Question 129Supportive, Palliative, and End-of-Life Care

    Which intervention is first-line for refractory dyspnea in a patient with advanced cancer?

    1. Low-dose systemic opioid Correct answer.
    2. Supplemental oxygen regardless of saturation
    3. Nebulized saline
    4. High-dose benzodiazepine alone

    Explanation

    Low-dose systemic opioids are first-line for refractory dyspnea because they reduce respiratory drive and the sensation of breathlessness. Oxygen is indicated only for hypoxemia, and benzodiazepines are reserved for associated anxiety.

  130. Question 130Supportive, Palliative, and End-of-Life Care

    Which medication is used to stimulate appetite in cancer-related anorexia?

    1. Megestrol acetate Correct answer.
    2. Levothyroxine for hypothyroidism
    3. Propranolol for performance status
    4. Metformin for insulin resistance

    Explanation

    Megestrol acetate is a progestin used to stimulate appetite in cancer-associated anorexia and cachexia. It carries risks of venous thromboembolism and adrenal suppression.

  131. Question 131Supportive, Palliative, and End-of-Life Care

    Which tool is validated for screening depression in patients with cancer?

    1. PHQ-9 Correct answer.
    2. CAGE questionnaire
    3. Braden scale
    4. Mini-Mental State Examination

    Explanation

    The PHQ-9 is a validated screening tool for depression and is commonly used in oncology. Somatic items may overlap with cancer symptoms, but the tool remains useful for identifying patients who need further evaluation.

  132. Question 132Supportive, Palliative, and End-of-Life Care

    A hospitalized patient with advanced cancer becomes acutely confused and agitated. After reversible causes are addressed, which management is most appropriate?

    1. Benzodiazepines as first-line for hyperactive delirium
    2. Discontinue all medications
    3. Low-dose haloperidol Correct answer.
    4. Physical restraints as first-line

    Explanation

    When nonpharmacologic measures are insufficient, a low-dose antipsychotic such as haloperidol is used for hyperactive delirium. Benzodiazepines are reserved for delirium due to alcohol or benzodiazepine withdrawal.

  133. Question 133Supportive, Palliative, and End-of-Life Care

    Which statement best describes palliative care?

    1. It is available only in inpatient hospice units
    2. It is limited to patients in the final days of life and requires a DNR order
    3. It can be provided alongside curative treatment from diagnosis Correct answer.
    4. It begins only when cancer-directed therapy stops

    Explanation

    Palliative care focuses on symptom management and quality of life and can be delivered at any stage, including alongside curative treatment. It is not limited to end-of-life care and does not require a DNR order.

  134. Question 134Supportive, Palliative, and End-of-Life Care

    A dying patient has audible gurgling from oral secretions. Which intervention is most appropriate?

    1. Reposition and give glycopyrrolate Correct answer.
    2. Restrict all oral care
    3. Place the patient in Trendelenburg position
    4. Suction the airway deeply every 15 minutes

    Explanation

    Audible secretions at the end of life are managed by repositioning and anticholinergic medication such as glycopyrrolate. Deep suctioning is distressing and can injure the airway.

  135. Question 135Supportive, Palliative, and End-of-Life Care

    A family member caring for a patient with terminal cancer reports sadness, sleep disturbance, and tearfulness before the patient's death. This most likely represents:

    1. Anticipatory grief Correct answer.
    2. Major depressive disorder
    3. Complicated grief
    4. Delirium

    Explanation

    Anticipatory grief is the normal grieving process that occurs before an expected death. It can include sadness, sleep changes, and tearfulness and does not necessarily indicate major depression.

  136. Question 136Supportive, Palliative, and End-of-Life Care

    Which document allows a patient to specify preferences for resuscitation and comfort-focused care and is signed by both patient and clinician?

    1. POLST form Correct answer.
    2. Do-not-resuscitate order
    3. Living will
    4. Durable power of attorney

    Explanation

    A POLST form converts patient preferences into actionable medical orders and is signed by the patient or surrogate and a clinician. A living will is a general statement, and a DNR order addresses only cardiopulmonary resuscitation.

  137. Question 137Supportive, Palliative, and End-of-Life Care

    A patient with prostate cancer reports new back pain and leg weakness. MRI shows epidural spinal cord compression. Which immediate intervention is most appropriate?

    1. Prescribe an opioid and arrange outpatient follow-up
    2. Start physical therapy and reassess in 48 hours
    3. Begin chemotherapy and obtain repeat imaging in 1 week
    4. Dexamethasone and urgent radiation oncology consult Correct answer.

    Explanation

    Epidural spinal cord compression is an emergency requiring immediate dexamethasone and urgent radiation oncology or surgical evaluation. Delay can lead to irreversible paraplegia and loss of bowel and bladder function.

  138. Question 138Supportive, Palliative, and End-of-Life Care

    A patient with squamous cell lung cancer has a corrected calcium of 14.2 mg/dL and is confused. After IV fluids, which agent is most appropriate?

    1. IV zoledronic acid Correct answer.
    2. Oral calcium carbonate
    3. Vitamin D supplementation
    4. Furosemide as monotherapy

    Explanation

    Hypercalcemia of malignancy is treated with IV fluids followed by an intravenous bisphosphonate such as zoledronic acid. Furosemide is used only after volume repletion and is not monotherapy.

  139. Question 139Supportive, Palliative, and End-of-Life Care

    A patient with Burkitt lymphoma develops hyperkalemia, hyperuricemia, and acute kidney injury after starting chemotherapy. Which intervention is most appropriate?

    1. Rasburicase plus IV hydration Correct answer.
    2. Administer oral potassium supplements daily
    3. Restrict IV fluids
    4. Give calcium-containing IV fluids for all patients

    Explanation

    Tumor lysis syndrome is managed with aggressive IV hydration and rasburicase to lower uric acid. Potassium supplements are contraindicated, and calcium is given only for symptomatic hypocalcemia.

  140. Question 140Supportive, Palliative, and End-of-Life Care

    A patient starting methadone for cancer pain should be monitored for which serious adverse effect?

    1. QT prolongation Correct answer.
    2. Severe hyperkalemia
    3. Pulmonary fibrosis
    4. Refractory hypertension

    Explanation

    Methadone can prolong the QT interval and cause torsades de pointes, so baseline and follow-up ECGs are recommended. Electrolytes such as potassium and magnesium should also be monitored.

  141. Question 141Supportive, Palliative, and End-of-Life Care

    A terminally ill patient has refractory dyspnea despite maximal treatment. Which statement about palliative sedation is correct?

    1. It relieves refractory symptoms without intent to hasten death Correct answer.
    2. It is euthanasia
    3. It can only be provided in an intensive care unit setting
    4. It requires withholding all comfort measures

    Explanation

    Palliative sedation is the use of sedatives to relieve refractory symptoms at the end of life and is not intended to hasten death. Comfort measures such as mouth care and positioning continue.

  142. Question 142Supportive, Palliative, and End-of-Life Care

    Which adverse effect is most associated with long-term dexamethasone use in advanced cancer?

    1. Symptomatic bradycardia
    2. Recurrent hypoglycemia
    3. Severe hyperkalemia
    4. Proximal myopathy Correct answer.

    Explanation

    Long-term corticosteroids cause proximal muscle weakness, hyperglycemia, hypokalemia, insomnia, and infection risk. Blood glucose and electrolytes should be monitored.

  143. Question 143Supportive, Palliative, and End-of-Life Care

    A patient on long-term morphine requires a higher dose to maintain the same pain relief. This finding is best described as:

    1. Addiction
    2. Physical dependence
    3. Pseudoaddiction
    4. Tolerance Correct answer.

    Explanation

    Tolerance is a pharmacologic decrease in response to a drug over time, requiring higher doses for the same effect. It is distinct from addiction, which involves compulsive use and harm.

  144. Question 144Supportive, Palliative, and End-of-Life Care

    A patient with lung cancer presents with facial swelling, distended neck veins, and dyspnea. Which initial intervention is most appropriate?

    1. Place a peripherally inserted central catheter in the right arm
    2. Administer diuretics as primary therapy
    3. Start anticoagulation for presumed pulmonary embolism
    4. Elevate the head of the bed and obtain urgent imaging Correct answer.

    Explanation

    These findings suggest superior vena cava syndrome. Initial management includes elevating the head of the bed and urgent imaging, followed by radiation, stenting, or other definitive therapy.

  145. Question 145Supportive, Palliative, and End-of-Life Care

    Which finding is most characteristic of impending death in the last days of life?

    1. Increased urine output
    2. Cheyne-Stokes respirations Correct answer.
    3. Hyperactive bowel sounds
    4. Sudden increase in appetite

    Explanation

    Cheyne-Stokes respirations, mottling, decreased urine output, and anorexia are common near the end of life. Increased appetite and urine output suggest improvement rather than impending death.

  146. Question 146Supportive, Palliative, and End-of-Life Care

    A patient with metastatic breast cancer takes extended-release morphine 30 mg PO every 12 hours with good baseline pain control but reports four episodes per day of severe breakthrough pain. Which prescription is most appropriate?

    1. Transdermal fentanyl 25 mcg/h every 72 hours as needed
    2. Increase the extended-release morphine dose to 60 mg PO every 12 hours
    3. Immediate-release morphine 5 to 10 mg PO as needed per episode Correct answer.
    4. Ibuprofen 400 mg PO as needed per episode

    Explanation

    The breakthrough dose is typically 10% to 20% of the total daily opioid dose (here 60 mg/day, giving roughly 6 to 12 mg of immediate-release morphine), given as needed. Frequent requirements for breakthrough doses should prompt reassessment and adjustment of the around-the-clock regimen rather than repeated as-needed dosing.

  147. Question 147Supportive, Palliative, and End-of-Life Care

    A patient with hormone receptor-positive breast cancer on endocrine therapy reports moderate fatigue that limits daily activity. Hemoglobin, mood screening, and sleep history are unremarkable. Which intervention is most appropriate initially?

    1. Encourage a graded aerobic exercise program with energy conservation Correct answer.
    2. Start epoetin alfa to raise the hemoglobin
    3. Recommend strict bed rest until energy returns
    4. Begin methylphenidate 10 mg each morning

    Explanation

    Exercise has the strongest evidence for cancer-related fatigue and is recommended as first-line management, along with energy conservation and treatment of contributing factors. Psychostimulants are reserved for selected patients with advanced disease, and erythropoiesis-stimulating agents are used only for chemotherapy-induced anemia with defined hemoglobin thresholds.

  148. Question 148Supportive, Palliative, and End-of-Life Care

    A patient with newly diagnosed cancer reports localized pain rated 3 out of 10 and has no contraindications to nonsteroidal agents. Which is the most appropriate initial analgesic?

    1. Oxycodone 5 mg every 4 hours on a scheduled basis
    2. Acetaminophen or an NSAID, with reassessment Correct answer.
    3. Oral dexamethasone 4 mg daily
    4. Transdermal fentanyl 12 mcg/h

    Explanation

    The WHO analgesic ladder begins with a nonopioid (acetaminophen or an NSAID) for mild pain, adding or substituting an opioid as severity increases. Regular reassessment determines whether escalation to a weak or strong opioid is needed.

  149. Question 149Supportive, Palliative, and End-of-Life Care

    Which intervention should be recommended to reduce oral mucositis in a patient receiving bolus 5-fluorouracil?

    1. Prophylactic oral acyclovir
    2. Prophylactic oral fluconazole
    3. Chlorhexidine gluconate 0.12% rinses four times daily
    4. Oral cryotherapy with ice chips during the infusion Correct answer.

    Explanation

    Oral cryotherapy produces local vasoconstriction, reducing delivery of the cytotoxic drug to the oral mucosa, and is recommended for bolus 5-fluorouracil and high-dose melphalan. Antifungal and antiviral prophylaxis do not prevent chemotherapy-induced mucosal injury, and chlorhexidine is not recommended for this purpose.

  150. Question 150Supportive, Palliative, and End-of-Life Care

    A patient with advanced sarcoma receiving escalating IV morphine develops diffuse myoclonus, allodynia, and visual hallucinations while pain remains poorly controlled. Renal function is normal. Which action is most appropriate?

    1. Continue escalating morphine and add lorazepam for the myoclonus
    2. Add haloperidol and continue the current morphine dose unchanged
    3. Administer naloxone 0.4 mg IV and discontinue all opioids
    4. Rotate to a different opioid at a reduced equianalgesic dose Correct answer.

    Explanation

    Myoclonus, hyperalgesia, and hallucinations with escalating opioid doses indicate opioid-induced neurotoxicity from accumulating metabolites, and the treatment is opioid rotation. Because of incomplete cross-tolerance, the equianalgesic dose of the new opioid is reduced by roughly 25% to 50%.

  151. Question 151Supportive, Palliative, and End-of-Life Care

    A patient with advanced lung disease and lung cancer is opioid-naive and reports disabling breathlessness at rest despite supplemental oxygen and bronchodilators. Which is the most appropriate next step?

    1. Lorazepam 1 mg IV every 6 hours as the sole agent
    2. Morphine 30 mg PO every 4 hours
    3. Nebulized furosemide 40 mg every 6 hours
    4. Low-dose oral immediate-release morphine titrated to effect Correct answer.

    Explanation

    Systemic opioids are first-line pharmacotherapy for refractory dyspnea and are started at low doses in opioid-naive patients, then titrated to symptom relief. Benzodiazepines are added only when anxiety coexists and are not used as monotherapy for breathlessness.

  152. Question 152Supportive, Palliative, and End-of-Life Care

    A patient with newly diagnosed multiple brain metastases from lung cancer has never had a seizure. Which approach to anticonvulsant therapy is recommended?

    1. Prophylactic phenytoin during whole-brain radiation therapy
    2. Prophylactic valproic acid combined with dexamethasone
    3. No routine prophylaxis; reserve anticonvulsants for patients who have had a seizure Correct answer.
    4. Prophylactic levetiracetam for all patients with brain metastases

    Explanation

    Anticonvulsant prophylaxis does not reduce the incidence of first seizures in patients with brain metastases and adds adverse effects and drug interactions. Therapy is started after a seizure has occurred, and non-enzyme-inducing agents are generally preferred.

  153. Question 153Supportive, Palliative, and End-of-Life Care

    A patient with active metastatic pancreatic cancer completes 6 months of therapeutic anticoagulation for a proximal leg DVT without bleeding complications while the cancer continues to progress. What is the most appropriate plan?

    1. Switch to aspirin 81 mg daily for thromboprophylaxis
    2. Stop anticoagulation now that 6 months of therapy are complete
    3. Place an inferior vena cava filter and stop anticoagulation
    4. Continue therapeutic anticoagulation indefinitely while the cancer remains active Correct answer.

    Explanation

    For cancer-associated thrombosis, anticoagulation is given for a minimum of 3 to 6 months and continued indefinitely while the cancer remains active or ongoing thrombotic risk persists, provided bleeding risk is acceptable. Inferior vena cava filters are reserved for patients with an absolute contraindication to anticoagulation.

  154. Question 154Supportive, Palliative, and End-of-Life Care

    A patient with extensive-stage small cell lung cancer has a serum sodium of 122 mEq/L, is clinically euvolemic, and has no neurologic symptoms. Which initial intervention is most appropriate?

    1. Hypertonic 3% saline infused at 1 mL/kg per hour
    2. Demeclocycline 300 mg PO twice daily
    3. Fluid restriction to 800 to 1000 mL per day Correct answer.
    4. 0.9% sodium chloride 1 L IV bolus

    Explanation

    Asymptomatic or mildly symptomatic euvolemic hyponatremia from SIADH is managed with fluid restriction and treatment of the underlying malignancy. Hypertonic saline is reserved for severe symptoms such as seizures or obtundation, and isotonic saline can worsen SIADH-related hyponatremia.

  155. Question 155Supportive, Palliative, and End-of-Life Care

    Which medication has the strongest randomized evidence for relieving painful chemotherapy-induced peripheral neuropathy?

    1. Duloxetine Correct answer.
    2. Amitriptyline
    3. Topical lidocaine 5% patch
    4. Gabapentin

    Explanation

    Duloxetine is the agent with positive randomized trial evidence for painful chemotherapy-induced peripheral neuropathy and is endorsed in guidelines. Gabapentin and pregabalin are frequently used but have failed to show benefit in controlled trials, and tricyclics are limited by anticholinergic effects in older adults.

  156. Question 156Supportive, Palliative, and End-of-Life Care

    Which statement about discussing goals of care with a patient who has advanced cancer is most accurate?

    1. The discussion should list every available treatment option in detail
    2. The discussion should be led by the family so the patient is spared distress
    3. The discussion should begin by exploring the patient's understanding and values Correct answer.
    4. The discussion should be deferred until all chemotherapy options are exhausted

    Explanation

    Goals-of-care conversations begin by assessing what the patient already understands and what matters most to them, then align recommendations with those values. These discussions occur alongside active treatment rather than only at the end of it, and the patient, not the family, is the primary participant.

  157. Question 157Supportive, Palliative, and End-of-Life Care

    Which statement best describes eligibility for the Medicare hospice benefit?

    1. The patient must be confined to home
    2. The patient must be unable to receive any further disease-directed therapy
    3. Prognosis of 6 months or less is certified and hospice is elected Correct answer.
    4. A do-not-resuscitate order must be in place

    Explanation

    Hospice eligibility requires physician certification that the prognosis is 6 months or less if the illness runs its usual course, plus the patient's election of the hospice benefit focused on comfort. A DNR order and home confinement are not required, and patients may withdraw the election at any time.

  158. Question 158Supportive, Palliative, and End-of-Life Care

    A patient with terminal cancer in the last days of life is minimally responsive, and the family requests intravenous fluids. Which approach is most appropriate?

    1. Start 3 L of IV normal saline daily to correct dehydration
    2. Defer the decision to the attending oncologist without discussion
    3. Place a nasogastric tube for enteral feeding
    4. Provide meticulous mouth care and explain that routine fluids rarely improve comfort Correct answer.

    Explanation

    In the actively dying patient, routine artificial hydration has not been shown to improve comfort and can worsen edema, ascites, pulmonary secretions, and vomiting. Meticulous mouth and lip care relieves thirst and dryness, and the family's concerns should be acknowledged and addressed directly.

  159. Question 159Supportive, Palliative, and End-of-Life Care

    A patient with advanced cancer who can no longer swallow and has no intravenous access requires opioids for severe pain. Which route is most appropriate?

    1. Rectal suppositories as the only acceptable alternative
    2. Intramuscular morphine every 4 hours
    3. Topical fentanyl gel applied to intact skin
    4. Subcutaneous infusion via a butterfly needle or subcutaneous catheter Correct answer.

    Explanation

    The subcutaneous route is preferred when the patient cannot swallow and has no intravenous access, because absorption is reliable, a continuous infusion can be delivered, and it is far less painful than repeated intramuscular injections. Rectal absorption is unpredictable, and compounded topical gels are not a dependable analgesic route.

  160. Question 160Supportive, Palliative, and End-of-Life Care

    A woman whose husband died of cancer 14 months ago continues to have intense yearning for him, feels her life is meaningless, avoids all reminders, and has stopped seeing friends. Which is the most appropriate action?

    1. Start an SSRI as the sole treatment
    2. Recommend a short course of benzodiazepines for sleep
    3. Refer for grief-focused psychotherapy such as complicated grief treatment Correct answer.
    4. Reassure her that this is normal grief and follow up in 6 months

    Explanation

    Persistent yearning, identity disruption, avoidance, and functional impairment beyond 12 months after a death suggest prolonged grief disorder, for which targeted psychotherapy is the first-line treatment. Antidepressants are adjunctive and are used mainly when depression coexists.

  161. Question 161Survivorship and Coordination of Care

    A patient who has completed adjuvant chemotherapy scores 5 on the NCCN Distress Thermometer. What is the most appropriate next step?

    1. Reassure the patient that some distress is normal at this stage
    2. Defer further assessment until the patient requests help
    3. Repeat the screening at the next scheduled annual visit
    4. Review the accompanying problem list and offer targeted referral Correct answer.

    Explanation

    A Distress Thermometer score of 4 or higher indicates moderate-to-severe distress and should prompt review of the problem list with referral to psychosocial services. Scores below 4 generally warrant routine monitoring only.

  162. Question 162Survivorship and Coordination of Care

    Which physical activity recommendation applies to most adults who have completed curative cancer treatment?

    1. Restriction of all activity until twelve months after the final treatment
    2. Moderate aerobic activity 150 minutes weekly plus strength work twice weekly Correct answer.
    3. Daily high-intensity interval training continued until fatigue resolves completely
    4. Light stretching for 60 minutes five days per week with no aerobic component

    Explanation

    Guidelines recommend at least 150 minutes of moderate-intensity (or 75 minutes of vigorous) aerobic activity weekly plus two sessions of resistance training. Regular activity reduces fatigue and improves function and quality of life in survivors.

  163. Question 163Survivorship and Coordination of Care

    Which pair of documents forms the core of a survivorship care plan?

    1. The insurance authorization and the billing record
    2. A treatment summary and a follow-up plan Correct answer.
    3. The chemotherapy order set and the consent forms
    4. The pathology report and the radiology reports

    Explanation

    A survivorship care plan consists of a treatment summary plus a written follow-up plan covering surveillance, screening for new cancers, late effects and psychosocial needs. It is delivered to the survivor and shared with the primary care clinician.

  164. Question 164Survivorship and Coordination of Care

    Which vaccine is contraindicated during active cytotoxic chemotherapy?

    1. Inactivated influenza vaccine
    2. Measles-mumps-rubella vaccine Correct answer.
    3. Tetanus and diphtheria toxoid booster
    4. Recombinant adjuvanted zoster vaccine

    Explanation

    Live attenuated vaccines can cause disseminated infection in immunocompromised hosts and should be deferred until immune function recovers. Inactivated and recombinant vaccines are not contraindicated and are generally recommended.

  165. Question 165Survivorship and Coordination of Care

    A postmenopausal woman is beginning adjuvant anastrozole. Which baseline test is recommended for skeletal surveillance?

    1. Whole-body bone scintigraphy
    2. Twenty-four-hour urinary calcium excretion
    3. Dual-energy x-ray absorptiometry Correct answer.
    4. Serum alkaline phosphatase

    Explanation

    Aromatase inhibitors accelerate bone loss, so baseline dual-energy x-ray absorptiometry with fracture risk assessment is recommended, with repeat imaging at intervals determined by results.

  166. Question 166Survivorship and Coordination of Care

    Which strategy is most effective for a survivor of lung cancer who continues to smoke?

    1. Referral to a peer support group without medication
    2. Brief advice to quit delivered at the annual survivorship visit
    3. Substitution of electronic cigarettes for combustible cigarettes
    4. Combination of behavioral counseling and pharmacotherapy Correct answer.

    Explanation

    Combining behavioral counseling with FDA-approved pharmacotherapy produces the highest quit rates and should be offered at every encounter. Continued smoking raises the risk of recurrence and second primary cancers.

  167. Question 167Survivorship and Coordination of Care

    A woman who was premenopausal at diagnosis has taken tamoxifen for five years for hormone receptor-positive breast cancer and remains premenopausal. What is the recommended duration of therapy?

    1. Stop tamoxifen after five years
    2. Continue tamoxifen to complete ten years of treatment Correct answer.
    3. Switch to an aromatase inhibitor for five years
    4. Continue tamoxifen for two additional years

    Explanation

    Extending tamoxifen to 10 years total reduces late recurrence and contralateral breast cancer in women who remain at risk. Aromatase inhibitor monotherapy is inappropriate in a premenopausal woman without ovarian suppression.

  168. Question 168Survivorship and Coordination of Care

    A 23-year-old survivor of Hodgkin lymphoma was never vaccinated against human papillomavirus. What should be recommended?

    1. Defer vaccination until age 30
    2. Vaccinate only if a high-grade cervical lesion develops
    3. Give the HPV vaccine series now Correct answer.
    4. No vaccination, because the upper age limit is 18 years

    Explanation

    Routine HPV vaccination is recommended through age 26, and catch-up vaccination should be offered to survivors who were not previously vaccinated. Shared clinical decision-making applies for adults aged 27 to 45.

  169. Question 169Survivorship and Coordination of Care

    A woman receiving adjuvant trastuzumab has an LVEF that falls from 60% to 44% on a repeat echocardiogram; she is asymptomatic. What is the most appropriate action?

    1. Discontinue trastuzumab permanently and begin an ACE inhibitor plus a beta blocker
    2. Continue trastuzumab at the same dose with no further imaging
    3. Hold trastuzumab and repeat the echocardiogram in about 4 weeks Correct answer.
    4. Reduce the trastuzumab dose by half and reimage in 6 months

    Explanation

    Trastuzumab is held when the absolute LVEF decline is 16% or more, or 10% or more to a value below the lower limit of normal, with reassessment typically in 3 to 4 weeks. If function recovers, treatment may be resumed.

  170. Question 170Survivorship and Coordination of Care

    A 29-year-old woman with newly diagnosed breast cancer wants children and is scheduled to begin chemotherapy in two weeks. What is the most appropriate action?

    1. Advise waiting two years after treatment before attempting pregnancy, since fertility will be preserved
    2. Reassure her that fertility usually returns after chemotherapy
    3. Refer promptly to reproductive endocrinology for fertility preservation Correct answer.
    4. Start a GnRH agonist alone as sufficient fertility preservation

    Explanation

    Referral for embryo or oocyte cryopreservation should occur before the first dose of gonadotoxic therapy, because delaying treatment reduces oocyte yield. Fertility counseling must precede treatment rather than follow it.

  171. Question 171Survivorship and Coordination of Care

    A survivor has painful tingling in both feet six months after paclitaxel and no motor weakness. Which medication has the best supporting evidence?

    1. Oxycodone extended release 10 mg twice daily
    2. Ibuprofen 600 mg three times daily
    3. Duloxetine 30 to 60 mg daily Correct answer.
    4. Gabapentin titrated to the maximum tolerated dose

    Explanation

    Duloxetine has the strongest evidence among pharmacologic options for painful chemotherapy-induced peripheral neuropathy. Nonpharmacologic measures and dose adjustment of the offending agent are also important components of care.

  172. Question 172Survivorship and Coordination of Care

    A survivor reports persistent fatigue seven months after completing chemotherapy. Which is the most appropriate first step?

    1. Reassure the patient that fatigue resolves spontaneously within twelve months of treatment
    2. Order a PET scan to exclude recurrent disease
    3. Prescribe a stimulant before other testing
    4. Screen for anemia, thyroid dysfunction, depression and sleep disturbance Correct answer.

    Explanation

    Cancer-related fatigue is a diagnosis of exclusion, so treatable contributors such as anemia, hypothyroidism, depression and sleep disturbance should be identified and managed first. Exercise and behavioral strategies are then emphasized.

  173. Question 173Survivorship and Coordination of Care

    Which finding in a breast cancer survivor treated with axillary dissection warrants prompt referral for lymphedema evaluation?

    1. Transient hand swelling that resolves within hours after a long flight
    2. Mild arm aching for a single day after unusually heavy yard work and gardening
    3. Bilateral breast tenderness in the week before menses
    4. Persistent arm heaviness with measurable circumferential increase Correct answer.

    Explanation

    Persistent heaviness with a measurable girth increase suggests early lymphedema, and early intervention with a certified therapist improves outcomes. Symptoms that resolve quickly and are clearly activity related are less concerning.

  174. Question 174Survivorship and Coordination of Care

    Which best describes the shared-care model of survivorship follow-up?

    1. Oncology and primary care agree on roles and exchange a care plan Correct answer.
    2. Follow-up is transferred to an urgent care or walk-in clinic setting
    3. Oncology retains all follow-up and the primary care clinician is not informed
    4. The primary care clinician assumes care without receiving any treatment summary

    Explanation

    In shared care the oncology team and primary care clinician explicitly divide surveillance, preventive care and late-effect monitoring, supported by a written care plan and ongoing communication. This model improves delivery of guideline-concordant preventive services.

  175. Question 175Survivorship and Coordination of Care

    A 70-year-old man has received leuprolide for two years for prostate cancer. Which survivorship measure is most appropriate?

    1. Discontinuation of all cardiovascular risk screening
    2. Baseline and periodic bone density testing with resistance exercise Correct answer.
    3. Annual prostate-specific antigen testing only, with no other monitoring
    4. Routine calcium supplementation without bone density assessment

    Explanation

    Androgen deprivation therapy causes bone loss, sarcopenia, metabolic changes and increased cardiovascular risk, so bone density testing, resistance exercise and metabolic monitoring are recommended. General preventive care continues during therapy.

  176. Question 176Survivorship and Coordination of Care

    A breast cancer survivor taking tamoxifen reports bothersome vaginal dryness and dyspareunia. What is the preferred initial management?

    1. Systemic estrogen replacement therapy started at the lowest effective dose
    2. Testosterone cream applied vaginally twice weekly
    3. Topical estrogen used daily without discussion of risk
    4. Nonhormonal moisturizers and lubricants with pelvic floor care Correct answer.

    Explanation

    Nonhormonal moisturizers and lubricants are first-line for genitourinary symptoms in hormone receptor-positive breast cancer because estrogen products carry theoretical risk. Vaginal estrogen may be considered only after shared decision-making with the oncology team.

  177. Question 177Survivorship and Coordination of Care

    A survivor reports difficulty initiating sleep three nights a week for four months. Which intervention is first-line?

    1. Diphenhydramine taken at bedtime as needed for sleep
    2. Extended-release melatonin at high dose
    3. Cognitive behavioral therapy for insomnia Correct answer.
    4. Zolpidem nightly for six months

    Explanation

    Cognitive behavioral therapy for insomnia is the recommended first-line treatment for chronic insomnia and produces durable benefit without dependence risk. Hypnotics are reserved for selected short-term situations.

  178. Question 178Survivorship and Coordination of Care

    Which approach best identifies cost-related distress among survivors during follow-up?

    1. Waiting for the patient to raise billing concerns spontaneously
    2. Referring all patients with unpaid balances directly to collections
    3. Reviewing the insurance policy alone without speaking with the patient about costs
    4. Asking directly about cost concerns and offering financial navigation Correct answer.

    Explanation

    Financial toxicity is common and underrecognized, so routine direct inquiry with referral to financial navigation, copay assistance and social work is recommended. Survivors often do not volunteer cost concerns.

  179. Question 179Survivorship and Coordination of Care

    A patient has completed resection and adjuvant chemotherapy for stage III colon cancer. When should the first surveillance colonoscopy occur?

    1. Ten years after the original diagnosis, as for average-risk adults
    2. One year after resection, or sooner if not complete preoperatively Correct answer.
    3. Five years after completion of adjuvant chemotherapy
    4. Only when symptoms or a rising CEA suggest recurrence

    Explanation

    After curative resection, colonoscopy is performed at about one year, then at three years if normal, then every five years. If the preoperative colonoscopy was incomplete, the interval schedule begins differently.

  180. Question 180Survivorship and Coordination of Care

    A survivor screens positive on the PHQ-2. What is the most appropriate next step?

    1. Reassure the patient that low mood is an expected part of cancer recovery
    2. Start an SSRI without further assessment
    3. Refer directly to inpatient psychiatry
    4. Administer the full PHQ-9 to grade severity Correct answer.

    Explanation

    A positive PHQ-2 should be followed by the full PHQ-9 to grade severity and guide treatment selection. Scores of 10 or higher generally warrant active treatment or referral.

  181. Question 181Survivorship and Coordination of Care

    A woman with prior mediastinal radiation is to receive doxorubicin. Which statement about anthracycline cardiotoxicity is correct?

    1. Radiation history does not alter cardiac risk
    2. Cardiotoxicity is unrelated to cumulative dose
    3. Dexrazoxane reduces cardiotoxicity in higher-risk patients Correct answer.
    4. Routine ejection fraction monitoring is unnecessary below 400 mg/m2

    Explanation

    Risk rises with cumulative doxorubicin dose, and prior chest radiation is an independent risk multiplier. Dexrazoxane is a cardioprotectant used when the anthracycline dose is high or cardiac risk is otherwise elevated.

  182. Question 182Survivorship and Coordination of Care

    A 32-year-old woman received mantle radiation for Hodgkin lymphoma at age 20. Which breast surveillance strategy is recommended?

    1. Annual mammography plus MRI starting 8 years after radiation Correct answer.
    2. Annual mammography beginning at age 40, as for average-risk women
    3. Breast self-examination alone every month
    4. One-time MRI at age 30 with no further imaging

    Explanation

    Survivors treated with chest radiation at a young age are at high risk of breast cancer, so guidelines recommend annual mammography with MRI beginning 8 years after radiation and not before age 25. This achieves earlier detection than average-risk screening.

  183. Question 183Survivorship and Coordination of Care

    A survivor has received denosumab for three years for osteoporosis. What is the most important consideration when stopping therapy?

    1. No taper or transitional therapy is needed because bone density gains persist indefinitely after the drug is stopped
    2. Repeat bone density testing in five years before making any decision
    3. Check serum calcium only if symptoms such as muscle cramps develop
    4. Transition to a bisphosphonate, or continue therapy, to prevent rebound fractures Correct answer.

    Explanation

    Stopping denosumab leads to rapid bone loss and rebound vertebral fractures, so a bisphosphonate should follow or therapy should be continued. Calcium and vitamin D status should be verified before each dose to avoid hypocalcemia.

  184. Question 184Survivorship and Coordination of Care

    A survivor is two years out from allogeneic transplant with chronic graft-versus-host disease. Which screening test detects early bronchiolitis obliterans syndrome?

    1. Serum alpha-1 antitrypsin level drawn annually
    2. Scheduled pulmonary function testing with spirometry Correct answer.
    3. Annual chest radiograph
    4. Sputum culture every six months

    Explanation

    Bronchiolitis obliterans syndrome is diagnosed by airflow obstruction on pulmonary function testing, which often precedes symptoms, so scheduled spirometry is recommended in patients with chronic graft-versus-host disease. Chest radiographs are insensitive for early disease.

  185. Question 185Survivorship and Coordination of Care

    A survivor treated with ipilimumab and nivolumab develops fatigue, headache and hypotension with low cortisol and low ACTH. What is the correct long-term management?

    1. Observation with repeat pituitary testing in six months
    2. A short steroid taper with the expectation of complete adrenal recovery over the next several months
    3. Fludrocortisone alone to restore blood pressure
    4. Lifelong glucocorticoid replacement with sick-day dose education Correct answer.

    Explanation

    Checkpoint inhibitor hypophysitis causes irreversible central adrenal insufficiency in most cases, requiring lifelong hydrocortisone replacement and education about stress dosing. Mineralocorticoid replacement is unnecessary because the renin-angiotensin axis remains intact.

  186. Question 186Survivorship and Coordination of Care

    Which element is essential in a survivorship care plan given after curative-intent cancer treatment?

    1. A schedule for the next chemotherapy cycle
    2. A treatment summary with surveillance recommendations Correct answer.
    3. A list of every dose reduction given
    4. A copy of the pathology report alone

    Explanation

    A survivorship care plan should contain a treatment summary and a clear follow-up plan covering surveillance, late effects, and health promotion. The plan is more than a single source document or a treatment schedule.

  187. Question 187Survivorship and Coordination of Care

    A survivor treated with mantle radiation for Hodgkin lymphoma 10 years ago reports fatigue and weight gain. Which test is most appropriate to screen for a radiation-related endocrine late effect?

    1. Serum TSH Correct answer.
    2. Hemoglobin A1c
    3. Serum cortisol
    4. Bone densitometry

    Explanation

    Neck and mantle radiation can damage the thyroid, and hypothyroidism may present years later with fatigue and weight gain. Annual TSH screening is recommended for at-risk survivors.

  188. Question 188Survivorship and Coordination of Care

    Which physical activity recommendation is appropriate for most cancer survivors after curative treatment?

    1. Bed rest until energy returns
    2. Only gentle stretching for ten minutes daily
    3. Daily unsupervised high-intensity interval training
    4. 150 minutes of moderate aerobic activity weekly Correct answer.

    Explanation

    Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week plus strength training for most survivors. Activity should be individualized, but prolonged bed rest is discouraged.

  189. Question 189Survivorship and Coordination of Care

    Which tool is recommended for routine distress screening in cancer survivors across the survivorship continuum?

    1. Distress Thermometer plus problem list Correct answer.
    2. PHQ-9 depression screen alone
    3. A single-item pain intensity scale
    4. GAD-7 anxiety screen alone

    Explanation

    The Distress Thermometer with its problem list is a validated rapid screen for global distress and identifies practical, emotional, and physical concerns. Depression and anxiety tools assess narrower domains.

  190. Question 190Survivorship and Coordination of Care

    A postmenopausal breast cancer survivor starting an aromatase inhibitor has a normal baseline DEXA. What bone density monitoring is recommended?

    1. Annual whole-body MRI
    2. DEXA every 5 years
    3. DEXA every 1 to 2 years Correct answer.
    4. No DEXA unless symptoms

    Explanation

    Aromatase inhibitors accelerate bone loss and fracture risk, so guidelines recommend bone density testing every 1 to 2 years during therapy. Calcium, vitamin D, and exercise are also addressed.

  191. Question 191Survivorship and Coordination of Care

    A breast cancer survivor reports mild memory and concentration problems 8 months after chemotherapy that interfere with work. What is the most appropriate initial management?

    1. Cognitive rehab; treat sleep and mood Correct answer.
    2. Stop endocrine therapy
    3. Immediate contrast-enhanced MRI of the brain
    4. Start donepezil daily

    Explanation

    Post-chemotherapy cognitive changes are common and usually managed first by addressing fatigue, sleep, mood, and with cognitive compensatory strategies. Neuroimaging is reserved for focal deficits or atypical features.

  192. Question 192Survivorship and Coordination of Care

    A survivor of allogeneic hematopoietic cell transplant is taking prednisone for chronic graft-versus-host disease. Which vaccine should be avoided?

    1. Recombinant zoster vaccine
    2. Inactivated influenza vaccine
    3. Live attenuated influenza vaccine Correct answer.
    4. Tetanus-diphtheria toxoid

    Explanation

    Live attenuated vaccines are contraindicated in patients with significant immunosuppression because of the risk of vaccine-derived infection. Inactivated and recombinant vaccines are generally preferred when indicated.

  193. Question 193Survivorship and Coordination of Care

    Which self-care practice is appropriate for a breast cancer survivor at risk for lymphedema?

    1. Routine prophylactic antibiotics
    2. Gradual arm exercise and weight control Correct answer.
    3. Daily prolonged arm elevation
    4. Avoid all use of the affected arm

    Explanation

    Progressive exercise and maintaining a healthy weight are supported strategies for reducing lymphedema risk and are not harmful when introduced gradually. Universal arm disuse and prophylactic antibiotics are not recommended.

  194. Question 194Survivorship and Coordination of Care

    A prostate cancer survivor treated with radical prostatectomy reports erectile dysfunction. Which initial management is appropriate?

    1. Immediate penile implant
    2. Pelvic radiation
    3. A PDE5 inhibitor Correct answer.
    4. Testosterone replacement

    Explanation

    PDE5 inhibitors are first-line pharmacologic therapy for erectile dysfunction after prostate cancer treatment, along with counseling and pelvic floor exercises. Surgical implants are reserved for refractory cases.

  195. Question 195Survivorship and Coordination of Care

    A survivor reports that oral endocrine therapy is unaffordable. What is the most appropriate initial step?

    1. Switch to intravenous chemotherapy
    2. Advise the patient to stop therapy
    3. Refer to financial navigation or assistance programs Correct answer.
    4. Tell the patient to skip doses on high-cost months

    Explanation

    Cost-related barriers should be addressed through financial navigation, manufacturer assistance, and insurance review before altering effective therapy. Stopping or skipping doses compromises outcomes.

  196. Question 196Survivorship and Coordination of Care

    A breast cancer survivor has limited shoulder range of motion and pain 3 months after surgery. Which referral is most appropriate?

    1. Physical therapy Correct answer.
    2. Oncology urgent care
    3. Chiropractic manipulation
    4. Pain clinic before any exercise

    Explanation

    Postoperative shoulder dysfunction is common and responds to physical therapy with stretching and strengthening. Urgent oncology evaluation is reserved for signs of infection, recurrence, or acute complications.

  197. Question 197Survivorship and Coordination of Care

    A head and neck cancer survivor has trismus and difficulty chewing 1 year after radiation. Which referral is most appropriate?

    1. Speech-language pathologist Correct answer.
    2. Oral surgeon
    3. Dietitian alone
    4. Neurologist

    Explanation

    Radiation-induced trismus and swallowing dysfunction are managed by a speech-language pathologist with jaw and swallowing therapy. A dietitian may support nutrition but does not treat the underlying impairment.

  198. Question 198Survivorship and Coordination of Care

    A 50-year-old survivor of Hodgkin lymphoma treated with mantle radiation at age 25 has a new systolic murmur and exertional dyspnea. Which late effect is most likely?

    1. Superior vena cava obstruction
    2. Radiation-associated valvular disease Correct answer.
    3. Chronic radiation pneumonitis
    4. Anthracycline-related cardiomyopathy

    Explanation

    Chest radiation can cause progressive valvular thickening and regurgitation years after exposure, often presenting with a murmur. Echocardiography is used to evaluate the valve and cardiac function.

  199. Question 199Survivorship and Coordination of Care

    A 45-year-old survivor of cervical cancer treated with pelvic radiation 18 months ago reports rectal bleeding and tenesmus. Which late effect is most likely?

    1. Chemotherapy-induced colitis
    2. Radiation cystitis
    3. Colorectal adenocarcinoma
    4. Radiation proctitis Correct answer.

    Explanation

    Pelvic radiation commonly causes rectal mucosal friability, bleeding, and tenesmus months to years later, consistent with radiation proctitis. Endoscopy is often needed to confirm and exclude recurrent cancer.

  200. Question 200Survivorship and Coordination of Care

    A breast cancer survivor taking tamoxifen has bothersome hot flashes. Which pharmacologic option is most appropriate?

    1. Venlafaxine Correct answer.
    2. Testosterone
    3. Paroxetine
    4. Conjugated equine estrogen

    Explanation

    Low-dose venlafaxine is effective for hot flashes and is preferred over strong CYP2D6 inhibitors such as paroxetine in patients taking tamoxifen. Hormonal therapy is generally avoided in breast cancer survivors.

AOCNP flashcards

32 cards. Read the term and the definition here. The deck at the top of this page is optional.

Hallmarks of cancer
Sustained proliferation, evasion of growth suppressors, apoptosis resistance, replicative immortality, angiogenesis, invasion and metastasis, and immune evasion are acquired capabilities enabling malignant growth.
Oncogene vs tumor suppressor
Oncogenes are gain-of-function drivers acting dominantly, such as RAS and MYC; tumor suppressors require loss of both alleles, such as TP53 and RB1, to remove growth restraint.
TNM staging meaning
T describes primary tumor size or invasion, N regional lymph node involvement, and M distant metastasis; the combined stage guides prognosis and therapy selection.
Tumor grade
Grade describes how differentiated tumor cells appear; well-differentiated low-grade tumors resemble normal tissue and generally have a better prognosis than poorly differentiated high-grade tumors.
Paraneoplastic hypercalcemia
Squamous cell lung cancer and multiple myeloma can secrete PTHrP or cause bone destruction, producing hypercalcemia with confusion, constipation, polyuria, and dehydration.
SIADH in small cell lung
Small cell lung cancer may cause syndrome of inappropriate ADH with euvolemic hyponatremia, concentrated urine, and low serum osmolality; treatment includes fluid restriction.
Cell cycle checkpoints
G1/S and G2/M checkpoints verify DNA integrity before replication and mitosis; loss of checkpoint control permits mutation accumulation and is targeted by some therapies.
Lung cancer screening criteria
Annual low-dose CT is recommended for adults aged 50 to 80 with at least 20 pack-years who currently smoke or quit within 15 years, after shared decision-making.
Colorectal screening start
Average-risk adults begin colorectal cancer screening at age 45 with colonoscopy every 10 years or annual FIT; hereditary syndromes or family history require earlier screening.
BRCA1/2 inheritance
BRCA1/2 pathogenic variants are autosomal dominant and raise lifetime breast and ovarian cancer risk; genetic counseling guides surveillance and risk-reducing surgery decisions.
Sensitivity and specificity
Sensitivity is true positives divided by all people with disease; specificity is true negatives divided by all people without disease; positive predictive value also depends on prevalence.
Lynch syndrome
Mismatch repair gene mutations cause Lynch syndrome, increasing colorectal and endometrial cancer risk; tumors typically show microsatellite instability or loss of MMR protein expression.
Core needle biopsy
Core needle biopsy removes tissue cores for histology and biomarker testing; it is preferred over fine-needle aspiration when tumor architecture or receptor status is needed.
Neoadjuvant vs adjuvant
Neoadjuvant therapy is given before surgery to shrink tumor and assess response; adjuvant therapy follows surgery to eradicate micrometastases and reduce recurrence risk.
SBRT
Stereotactic body radiation therapy delivers high-dose radiation in few fractions with precise targeting, used for small lung tumors, oligometastases, and some prostate cancers.
Cell-cycle-specific chemotherapy
Antimetabolites act mainly in S phase, while taxanes and vinca alkaloids act in M phase; alkylating agents and platinum compounds are cell-cycle nonspecific DNA-damaging agents.
Checkpoint inhibitor mechanism
PD-1, PD-L1, and CTLA-4 inhibitors release brakes on T cells, restoring antitumor immunity; immune-related adverse events can affect skin, gut, lungs, liver, and endocrine organs.
Trastuzumab target
Trastuzumab is a monoclonal antibody against HER2, used in HER2-amplified breast and gastric cancers; baseline and periodic cardiac function monitoring is required.
Autologous transplant
Autologous stem cell transplant uses the patient's own collected stem cells to rescue bone marrow after high-dose chemotherapy, commonly in multiple myeloma and lymphoma.
Phase III trial
Phase III trials compare a new treatment with standard therapy in large populations to measure efficacy and adverse effects; results support regulatory approval and practice change.
Febrile neutropenia definition
Fever of 38.3 C once or 38.0 C sustained plus absolute neutrophil count below 500 cells/microL; obtain cultures and start empiric broad-spectrum antibiotics promptly.
Opioid conversion
When switching opioids, calculate the equianalgesic dose, reduce for incomplete cross-tolerance, and reassess; oral morphine to intravenous morphine is approximately 3 to 1.
Highly emetogenic prophylaxis
Regimens such as cisplatin require a 5-HT3 antagonist, an NK1 receptor antagonist, and dexamethasone, often with olanzapine, before and after chemotherapy.
Tumor lysis syndrome
Rapid tumor cell death releases potassium, phosphate, and nucleic acids, causing hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia; treat with hydration and urate-lowering therapy.
Hospice eligibility
Hospice is appropriate when prognosis is about 6 months or less and goals focus on comfort; palliative care can be provided alongside curative treatment.
Hypercalcemia management
Intravenous fluids restore volume, bisphosphonates or denosumab inhibit bone resorption, and calcitonin lowers calcium rapidly; monitor renal function and electrolytes.
Survivorship care plan
A survivorship care plan summarizes cancer treatment, surveillance schedule, potential late effects, health promotion, and coordination between oncology and primary care.
Anthracycline cardiotoxicity
Doxorubicin and related drugs cause dose-dependent cardiomyopathy; baseline and periodic ejection fraction monitoring with echocardiography or MUGA is recommended, especially with cardiac risk factors.
Fertility preservation
Before gonadotoxic therapy, discuss sperm banking, oocyte or embryo cryopreservation, and possibly ovarian suppression; referral should occur before treatment starts.
Distress screening
Use a validated tool such as the NCCN Distress Thermometer at diagnosis and intervals; distress affects adherence and quality of life and warrants appropriate referral.
Lymphedema risk reduction
After axillary surgery or radiation, monitor arm circumference, educate about skin care and gradual exercise, and refer for compression or physical therapy if swelling occurs.
Chemotherapy-induced neuropathy
Taxanes, platinum agents, and vinca alkaloids can cause sensory peripheral neuropathy; assess gait, falls, and function, and adjust treatment when symptoms are severe.

AOCNP study guide

Science of Oncology: Carcinogenesis, Gene Classes, Growth Kinetics, and Metastasis

The central framework

Carcinogenesis is a multistep process of initiation (irreversible DNA damage), promotion (clonal expansion of the initiated cell), and progression (accumulating alterations and invasive capacity). Questions usually test whether you can assign a gene or process to the correct functional class.

Genes and pathways

  • Oncogenes act dominantly: one activating mutation, amplification, or translocation suffices. Examples: RAS, MYC, HER2/ERBB2, EGFR, BCR-ABL.
  • Tumor suppressors are recessive at the cellular level (Knudson two-hit): both alleles must be lost or silenced. Examples: TP53, RB1, APC, PTEN, BRCA1/2.
  • Checkpoints: the G1/S restriction point (RB–E2F, p53–p21) and G2/M. Drug sensitivity tracks with proliferative fraction and cell-cycle phase.

Hallmarks of cancer

Sustained proliferation, evasion of growth suppressors, resistance to apoptosis, replicative immortality (telomerase), induced angiogenesis, invasion and metastasis, genomic instability, immune evasion, deregulated metabolism (Warburg effect), and tumor-promoting inflammation.

Growth kinetics and metastasis

Tumors follow roughly Gompertzian growth: the growth fraction falls as mass rises. The log-kill hypothesis states that a dose kills a constant fraction, not a constant number, of cells - which is why adjuvant therapy against microscopic residual disease outperforms the same regimen against bulky disease. Metastasis requires epithelial–mesenchymal transition, intravasation, survival in circulation, extravasation, and colonization of a permissive niche ("seed and soil").

Worked example

A tumor shows biallelic BRCA1 loss with no detectable protein. That is a tumor suppressor pattern causing homologous-recombination deficiency, predicting sensitivity to platinum agents and PARP inhibitors.

Rule of thumb: oncogene = stuck accelerator (one hit); tumor suppressor = failed brakes (usually two hits).

Cancer Prevention, Detection, and Diagnosis: Screening, Risk, Tissue, and Staging

Screening versus diagnosis

Screening applies a test to asymptomatic, average-risk people; diagnosis confirms disease in symptomatic patients or those with abnormal screening. Know the major programs: colorectal screening from age 45 (colonoscopy or stool-based testing), biennial mammography from 40–74, cervical HPV-based testing beginning at 21–25, annual low-dose CT for lung cancer in adults 50–80 with at least 20 pack-years who currently smoke or quit within 15 years, and shared decision-making for PSA.

Risk and genetics

Separate population screening from high-risk surveillance (earlier or intensified breast MRI for BRCA carriers; colonoscopy every 1–2 years in Lynch syndrome). Germline testing is offered when personal or family history suggests hereditary predisposition. Somatic tumor profiling guides therapy but does not replace germline testing.

Tissue, grade, and stage

Tissue diagnosis is generally required. Grade describes differentiation; stage describes anatomic and biologic extent. TNM combines tumor size and invasion (T), nodes (N), and metastases (M), with separate clinical (cTNM), pathologic (pTNM), and post-neoadjuvant (ypTNM) classifications. Performance status is an independent prognostic factor.

Tumor markers

CA-125, CEA, CA 19-9, AFP, hCG, CA 15-3, and PSA are used mainly to monitor response and detect recurrence; only a few (AFP and hCG in germ cell tumors, PSA in prostate cancer) contribute to diagnosis or staging.

Worked example

A 62-year-old who smoked 30 pack-years and quit 3 years ago asks about lung screening. He meets criteria (age 50–80, at least 20 pack-years, quit within 15 years) for annual low-dose CT.

Traps: equating a rising tumor marker with relapse, treating on the basis of a marker without imaging or tissue confirmation, and confusing grade with stage.

Cancer Treatment Modalities: Local Therapy, Systemic Agents, and Response Assessment

Local therapy

Surgery aims at complete resection (R0 = negative margins, R1 = microscopic, R2 = gross residual) and may be curative, debulking, or palliative. Radiation is delivered as external beam, brachytherapy, or stereotactic ablative therapy; effect depends on total dose, fractionation, volume, and radiosensitizers. Acute toxicities occur during treatment (mucositis, dermatitis, fatigue); late toxicities emerge months to years later (fibrosis, xerostomia, second malignancy).

Systemic therapy

  • Cytotoxic chemotherapy is classified by mechanism (alkylators, platinums, antimetabolites, topoisomerase inhibitors, taxanes, vinca alkaloids) and by cell-cycle specificity, which drives scheduling.
  • Targeted agents block defined alterations: tyrosine kinase inhibitors, monoclonal antibodies, PARP inhibitors (homologous-recombination deficiency), CDK4/6 inhibitors (HR-positive breast cancer), proteasome inhibitors.
  • Immune checkpoint inhibitors release T-cell brakes. Immune-related adverse events (colitis, pneumonitis, thyroiditis, hypophysitis) may appear weeks to months after starting and are managed with corticosteroids and interruption, not continued dosing.
  • Endocrine therapy and hematopoietic stem cell transplant apply to specific diseases.

Measuring benefit

RECIST 1.1 sums target-lesion longest diameters: complete response = disappearance; partial response = at least 30% decrease; progressive disease = at least 20% increase with an absolute increase of at least 5 mm, or new lesions; otherwise stable disease.

Worked example

Baseline sum 100 mm, follow-up 68 mm = 32% decrease, so partial response. A rise from 10 mm to 12 mm is 20% but only 2 mm absolute - not progressive disease, because both criteria must be met.

Rule of thumb: phase I = safety and dosing, II = activity, III = comparative effectiveness; marker change alone is not a RECIST response.

Supportive, Palliative, and End-of-Life Care: Toxicity Control, Pain, and Goals

Symptom and toxicity management

Antiemetic prophylaxis is matched to emetogenicity: highly emetogenic regimens receive a 5-HT3 antagonist plus an NK1 antagonist plus dexamethasone, often with olanzapine, plus coverage for delayed nausea. Febrile neutropenia - one temperature of 38.3 °C or higher, or 38.0 °C sustained over an hour, with ANC below 500/µL (or below 1000 predicted to fall) - requires empiric broad-spectrum antibiotics within about 60 minutes. Colony-stimulating factor prophylaxis is standard when febrile neutropenia risk is 20% or greater. Mucositis is managed with oral care, analgesia, and hydration.

Pain and palliation

Follow the analgesic ladder, prescribe around-the-clock dosing with rescue doses, add adjuvants (gabapentinoids, corticosteroids, bisphosphonates), and proactively manage opioid-induced constipation. Palliative care is symptom-focused care delivered alongside disease-directed treatment from diagnosis; hospice is a benefit for patients with a prognosis of about 6 months or less who elect comfort-focused care. They are not synonyms.

Communication and end of life

Document goals-of-care discussions, advance directives, and POLST orders early. In the final days, treat dyspnea, pain, agitation, and secretions with opioids, benzodiazepines, and anticholinergics, and address caregiver burden and bereavement.

Worked example

A patient taking morphine 30 mg PO daily rotates to oral hydromorphone at roughly a 5:1 ratio, giving about 6 mg/day in divided doses, with a rescue dose around 10% of the daily total and monitoring for sedation and respiratory depression.

Traps: withholding opioids from a dying patient for fear of addiction, calling palliative care "giving up," and delaying antibiotics in febrile neutropenia.

Survivorship and Coordination of Care: Care Plans, Late Effects, and Transitions

Survivorship care

Every patient completing curative-intent treatment needs a survivorship care plan: treatment summary, surveillance schedule, late-effect risks, health-promotion advice, and explicit designation of who is responsible for each follow-up element. Shared care with primary care works only when responsibilities are documented.

Late and long-term effects

Screen for organ toxicity (anthracycline or trastuzumab cardiomyopathy requiring periodic echocardiography; cisplatin nephrotoxicity and ototoxicity; bleomycin pulmonary toxicity), peripheral neuropathy, lymphedema, premature ovarian insufficiency and infertility, sexual dysfunction, osteoporosis, hypothyroidism after neck radiation, and secondary malignancies (therapy-related AML/MDS, radiation-associated solid tumors). Distress, depression, anxiety, fear of recurrence, cognitive complaints, and financial toxicity are common and should be screened with a validated tool at intervals.

Health promotion and coordination

Counsel on physical activity, weight management, tobacco cessation, alcohol limits, sun protection, immunizations, and bone health. Fertility preservation must be discussed before gonadotoxic therapy. Coordinate transfers of care, reconcile oral anticancer medications for adherence and drug interactions, and ensure risk-appropriate screening (for example, earlier breast MRI for BRCA carriers) continues.

Worked example

A 45-year-old woman treated with doxorubicin and chest-wall radiation reports fatigue and palpitations 3 years later. Her survivorship plan calls for periodic echocardiography and cardiovascular risk-factor management; new cardiac symptoms warrant prompt evaluation rather than being attributed automatically to "cancer fatigue."

Traps: dismissing new symptoms as expected late effects without evaluation, omitting secondary-cancer surveillance, and neglecting fertility and sexual health discussions.

AOCNP cheat sheet

Quick reference

Science of Oncology

  • Hallmarks of cancer include sustained proliferative signaling, evasion of growth suppressors, resistance to apoptosis, replicative immortality, angiogenesis induction, tissue invasion and metastasis, and immune evasion.

  • Oncogenes are gain-of-function drivers that act dominantly (for example RAS, MYC, HER2); tumor suppressors such as TP53, RB1, and APC generally require loss of both alleles to remove growth restraint.

  • TNM staging classifies T by primary tumor size or invasion, N by regional lymph node involvement, and M by distant metastasis; the combined stage guides prognosis and treatment selection.

  • Grade describes tumor cell differentiation and is distinct from stage; well-differentiated low-grade tumors generally have a better prognosis than poorly differentiated high-grade tumors.

  • The cell cycle proceeds G1 to S DNA synthesis to G2 to M; G1/S and G2/M checkpoints verify DNA integrity, and loss of checkpoint control permits mutation accumulation.

  • Tumor markers such as AFP, CA-125, CEA, and PSA are not diagnostic alone; they are most useful for monitoring disease and in defined screening contexts.

  • Paraneoplastic syndromes include SIADH with small cell lung cancer, hypercalcemia with squamous cell lung cancer and myeloma, Cushing syndrome from ectopic ACTH, and Eaton-Lambert syndrome with small cell lung cancer.

  • Metastasis occurs through lymphatic or hematogenous spread, with lung, liver, bone, and brain as common distant sites; carcinogenesis is a multistep process of initiation, promotion, and progression.

Quick reference

Cancer Prevention, Detection, and Diagnosis

  • Breast cancer screening uses mammography at intervals of 1 to 2 years for average-risk women in their 40s to 70s, with supplemental MRI reserved for appropriately defined high-risk groups.

  • Average-risk colorectal cancer screening begins at age 45 with colonoscopy every 10 years or annual FIT; hereditary syndromes and family history require earlier and more intensive screening.

  • Cervical cancer screening uses HPV testing every 5 years or co-testing every 5 years from ages 30 to 65; cytology alone every 3 years is an option for ages 21 to 29.

  • Annual low-dose CT lung cancer screening is recommended for adults aged 50 to 80 with at least a 20 pack-year history who currently smoke or quit within 15 years, after shared decision-making.

  • Prostate cancer screening with PSA is a shared decision for men aged 55 to 69; routine PSA screening is not recommended for men older than 70 or with limited life expectancy.

  • BRCA1/2 pathogenic variants are autosomal dominant and increase breast and ovarian cancer risk; Lynch syndrome from mismatch repair mutations increases colorectal and endometrial cancer risk.

  • Sensitivity equals true positives divided by all people with disease; specificity equals true negatives divided by all people without disease; positive predictive value also depends on disease prevalence.

  • Core needle biopsy is preferred when tumor histology, architecture, or receptor status is needed; fine-needle aspiration is useful for cytology but may not provide tissue architecture.

Quick reference

Cancer Treatment Modalities

  • Surgery provides local control, debulking, or palliation; neoadjuvant therapy is given before surgery to shrink tumor and assess response, while adjuvant therapy follows surgery to eradicate micrometastases.

  • External beam radiation is commonly fractionated, SBRT delivers high doses in few fractions with precise targeting, and brachytherapy places a radioactive source near or inside the tumor.

  • Alkylating agents and platinum compounds are cell-cycle nonspecific; antimetabolites act mainly in S phase; taxanes and vinca alkaloids act in M phase.

  • Targeted therapies include tyrosine kinase inhibitors for EGFR or ALK, monoclonal antibodies such as trastuzumab for HER2 and rituximab for CD20, and angiogenesis inhibitors such as bevacizumab against VEGF.

  • Immune checkpoint inhibitors targeting PD-1, PD-L1, or CTLA-4 restore antitumor T-cell activity and can cause immune-related adverse events in skin, gut, lung, liver, and endocrine organs.

  • Hormone therapy includes tamoxifen as a selective estrogen receptor modulator, aromatase inhibitors in postmenopausal estrogen receptor-positive breast cancer, and androgen deprivation therapy in prostate cancer.

  • Autologous stem cell transplant uses the patient's own stem cells to rescue marrow after high-dose chemotherapy; allogeneic transplant uses donor cells and carries graft-versus-host disease risk.

  • Clinical trial phases are I for safety and dose finding, II for efficacy, III for comparison with standard therapy, and IV for post-marketing surveillance; RECIST categories are complete response, partial response, stable disease, and progressive disease.

Quick reference

Supportive, Palliative, and End-of-Life Care

  • The WHO analgesic ladder advances from non-opioids to weak opioids to strong opioids, with adjuvant agents for neuropathic or bone pain and reassessment after each change.

  • When converting opioids, calculate the equianalgesic dose, reduce for incomplete cross-tolerance, and reassess; oral morphine to intravenous morphine is approximately 3 to 1.

  • Highly emetogenic chemotherapy such as cisplatin requires a 5-HT3 antagonist, an NK1 receptor antagonist, and dexamethasone, often with olanzapine added.

  • Febrile neutropenia is fever of 38.3 C once or 38.0 C sustained with an absolute neutrophil count below 500 cells/microL; obtain cultures and give empiric broad-spectrum antibiotics promptly.

  • Primary G-CSF prophylaxis is considered when febrile neutropenia risk is approximately 20% or higher; colony-stimulating factors reduce duration and severity of neutropenia.

  • Tumor lysis syndrome causes hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia; management includes hydration, allopurinol or rasburicase, and electrolyte monitoring.

  • Hypercalcemia of malignancy is treated with intravenous fluids, a bisphosphonate or denosumab, and calcitonin for rapid lowering; renal function and electrolytes require monitoring.

  • Hospice is appropriate when prognosis is about 6 months or less and goals focus on comfort; palliative care can be provided concurrently with curative-intent treatment and advance directives guide future care.

Quick reference

Survivorship and Coordination of Care

  • A survivorship care plan includes a treatment summary, surveillance schedule, potential late effects, health promotion recommendations, and clear coordination between oncology and primary care.

  • Anthracycline cardiotoxicity is dose-dependent; baseline and periodic ejection fraction monitoring by echocardiography or MUGA is recommended, especially with additional cardiac risk factors.

  • Secondary malignancies can follow radiation or chemotherapy, particularly alkylating agents and topoisomerase inhibitors; long-term surveillance depends on prior exposures and age at treatment.

  • Fertility preservation should be discussed before gonadotoxic therapy; options include sperm banking, oocyte or embryo cryopreservation, and possibly ovarian suppression during treatment.

  • Distress should be screened at diagnosis and at intervals with a validated tool such as the NCCN Distress Thermometer; significant distress affects adherence and quality of life and warrants referral.

  • Lymphedema risk rises after axillary surgery or regional radiation; monitoring arm circumference, skin care education, gradual exercise, and early referral for compression or physical therapy are recommended.

  • Chemotherapy-induced peripheral neuropathy from taxanes, platinum agents, and vinca alkaloids requires assessment of sensation, gait, falls, and function, with treatment adjustment when symptoms are severe.

  • Surveillance after curative treatment follows site-specific guidelines and avoids unnecessary imaging; multidisciplinary coordination and timely handoff to primary care support long-term survivorship.

AOCNP key terms

Carcinogenesis

The multistep process by which normal cells accumulate genetic and epigenetic changes that permit uncontrolled growth, survival, and eventual invasion. It usually progresses from initiation through promotion to malignant transformation.

Related: Oncogene, Tumor suppressor gene, Angiogenesis
Oncogene

A gene that, when mutated, amplified, or overexpressed, pushes cells to divide when they should not. It arises from a normal proto-oncogene and acts dominantly, so one altered copy can contribute to cancer.

Related: Carcinogenesis, Tumor suppressor gene
Tumor suppressor gene

A gene whose normal product restrains cell division, repairs damaged DNA, or triggers death of injured cells. Cancer typically requires loss of function in both copies, removing an important brake on growth.

Related: Oncogene, Apoptosis, Cell cycle checkpoints
Cell cycle checkpoints

Surveillance points, chiefly at the G1-to-S and G2-to-M transitions, where a cell verifies DNA integrity and chromosome alignment before dividing. Loss of these controls lets damaged DNA be copied and passed on.

Related: Apoptosis, Tumor suppressor gene, Chemotherapy
Angiogenesis

Formation of new blood vessels from existing ones. Tumors stimulate this process to obtain oxygen and nutrients and to create routes for cells to enter the bloodstream and spread.

Related: Metastasis, Carcinogenesis
Apoptosis

Programmed cell death, an orderly self-destruction that removes damaged or unneeded cells. Many cancers evade it by altering pro- and anti-apoptotic proteins, so injured cells survive and accumulate further mutations.

Related: Tumor suppressor gene, Cell cycle checkpoints
Metastasis

Spread of malignant cells from the primary tumor through blood or lymphatic channels to distant organs, where secondary tumors develop. It is the leading cause of death from solid tumors.

Related: Angiogenesis, Staging
Staging

A standardized description of how far cancer has spread, based on tumor size, regional lymph node involvement, and distant spread. Stage guides prognosis, treatment selection, and trial eligibility.

Related: Metastasis, Grading, Biopsy
Grading

Microscopic assessment of how closely tumor cells resemble the normal tissue they came from, ranging from well to poorly differentiated. Higher grade generally indicates faster growth and more aggressive behavior.

Related: Staging, Biopsy
Biopsy

Removal of a tissue sample for examination under the microscope and for molecular testing. It is the definitive way to confirm cancer, establish histology and grade, and guide treatment selection.

Related: Grading, Staging, Biomarker
Screening

Testing people who have no symptoms to find cancer or precancerous changes at an earlier, more curable stage. It is worthwhile only when the test is accurate and early treatment improves outcomes.

Related: Tumor markers, Risk factor
Tumor markers

Proteins, hormones, or other substances measured in blood or tissue that may be elevated in certain cancers. They are used mainly to track response and detect recurrence rather than to establish a diagnosis.

Related: Screening, Staging
Germline mutation

An inherited DNA alteration present in nearly every cell of the body and potentially passed to children. Variants such as BRCA1 or BRCA2 mutations raise cancer risk and can influence treatment decisions.

Related: Risk factor, Targeted therapy
Risk factor

A behavior, exposure, or characteristic linked to a higher likelihood of developing cancer, such as tobacco use, ionizing radiation, obesity, or older age. Some are modifiable and become targets for prevention.

Related: Screening, Germline mutation
Neoadjuvant therapy

Treatment given before the main local treatment, usually to shrink a tumor so surgery or radiation is more effective or feasible. It also provides an early indication of how sensitive the cancer is.

Related: Adjuvant therapy, Biomarker
Adjuvant therapy

Treatment given after the primary tumor has been removed when no measurable disease remains. Its purpose is to eliminate microscopic residual cancer and reduce the chance of recurrence.

Related: Neoadjuvant therapy, Chemotherapy
Chemotherapy

Cytotoxic drugs that preferentially kill rapidly dividing cells. They are usually given as multi-drug regimens over repeated cycles and act throughout the body, so normal dividing tissues are also injured.

Related: Myelosuppression, Extravasation, Cell cycle checkpoints
Targeted therapy

Agents designed to block a specific molecule or pathway that a cancer depends on, such as a mutant kinase or overexpressed receptor. Benefit often requires the tumor to carry the matching biomarker.

Related: Biomarker, Immunotherapy
Immunotherapy

Treatment that activates or redirects the immune system to attack cancer. Checkpoint inhibitors that block PD-1, PD-L1, or CTLA-4 are common examples and can produce long-lasting responses in some patients.

Related: Immune-related adverse events, CAR T-cell therapy
CAR T-cell therapy

A patient's T cells are collected, genetically engineered to carry a receptor that recognizes a tumor antigen, and reinfused after lymphodepleting chemotherapy. It can cause cytokine release syndrome and neurologic toxicity.

Related: Cytokine release syndrome, Immunotherapy
Hematopoietic stem cell transplant

Infusion of blood-forming stem cells to restore marrow function after high-dose chemotherapy or radiation. Autologous transplants use the patient's own cells; allogeneic transplants come from a donor and carry graft-versus-host risk.

Related: Myelosuppression, Febrile neutropenia
Radiation therapy

Use of ionizing radiation to damage DNA and kill cancer cells within a defined volume of tissue. It is delivered by external beams or implanted sources and is often combined with systemic treatment.

Related: Mucositis, Chemotherapy
Hormone therapy

Treatment that lowers hormone levels or blocks hormone receptors in cancers that grow in response to hormones, such as many breast and prostate cancers. Examples include tamoxifen, aromatase inhibitors, and androgen deprivation.

Related: Targeted therapy
Biomarker

A measurable biological feature, such as a gene mutation, protein level, or gene amplification, that informs diagnosis, prognosis, or the likelihood of responding to a specific drug.

Related: Targeted therapy, Biopsy
Febrile neutropenia

Fever occurring with a severely low neutrophil count. It is an oncologic emergency requiring immediate blood cultures and empiric broad-spectrum antibiotics, because infection can progress rapidly to sepsis.

Related: Myelosuppression, Chemotherapy
Myelosuppression

Suppression of bone marrow activity that lowers red cells, white cells, and platelets after chemotherapy or radiation. Counts usually reach their lowest point seven to fourteen days after treatment, raising infection and bleeding risk.

Related: Febrile neutropenia, Chemotherapy
Extravasation

Leakage of a drug, particularly a vesicant, out of the vein into surrounding tissue. It can cause blistering and tissue death, so the infusion is stopped immediately and site-specific measures are started.

Related: Chemotherapy
Immune-related adverse events

Autoimmune toxicities caused by checkpoint inhibitors, commonly affecting skin, colon, liver, lungs, and endocrine glands. They may appear weeks after treatment and are managed with corticosteroids and drug interruption.

Related: Immunotherapy
Cytokine release syndrome

A systemic inflammatory reaction after CAR T-cell therapy or bispecific antibodies, marked by fever, hypotension, hypoxia, and organ dysfunction. Severity is graded, and treatment includes supportive care and tocilizumab.

Related: CAR T-cell therapy, Immunotherapy
Mucositis

Painful inflammation and ulceration of the mouth or gastrointestinal lining caused by chemotherapy or radiation. It can interfere with eating and speaking and creates a portal for infection.

Related: Radiation therapy, Chemotherapy
Peripheral neuropathy

Nerve damage from drugs such as platinum agents, taxanes, and vinca alkaloids, producing numbness, tingling, burning, or weakness in the hands and feet. It is often dose-limiting and may persist after treatment stops.

Related: Chemotherapy, Late effects
Malignant spinal cord compression

Compression of the spinal cord or cauda equina by tumor, causing back pain, weakness, sensory change, or bowel and bladder dysfunction. Urgent corticosteroids and imaging are needed to preserve neurologic function.

Related: Metastasis, Palliative care
Palliative care

Interdisciplinary care that relieves symptoms and addresses physical, emotional, social, and spiritual needs at any stage of serious illness. It is delivered alongside disease-directed treatment, not only near the end of life.

Related: Hospice care, Goals of care, Performance status
Hospice care

Comfort-focused care for people with a life expectancy of about six months or less who have stopped disease-directed treatment. It emphasizes symptom control, family support, and quality of life.

Related: Palliative care, Goals of care
Goals of care

The shared understanding among patient, family, and clinicians about which outcomes matter most and which treatments fit those priorities. These discussions guide decisions about further therapy versus comfort-focused care.

Related: Palliative care, Advance care planning, Hospice care
Advance care planning

Ongoing conversation and documentation of a person's wishes for future medical care, including a chosen health care proxy and written directives. It helps ensure decisions reflect the patient's values if they lose capacity.

Related: Goals of care, Hospice care
Performance status

A standardized rating, such as the ECOG or Karnofsky score, of how independently a patient manages daily activities. It predicts tolerance of treatment and heavily influences whether intensive therapy is offered.

Related: Palliative care, Goals of care
Survivorship care plan

A written summary given to a cancer survivor and their clinicians that lists treatments received, recommended surveillance, and possible late effects. It supports handoff and coordination between oncology and primary care.

Related: Late effects, Distress screening
Late effects

Health problems caused by cancer treatment that emerge months to years after therapy, such as heart damage from anthracyclines, infertility, neuropathy, or second cancers. Surveillance depends on the specific treatments received.

Related: Survivorship care plan, Peripheral neuropathy
Distress screening

Routine use of a brief validated questionnaire to detect emotional, practical, and physical concerns in people with cancer. Positive screens trigger referral to social work, psychology, or other supportive services.

Related: Survivorship care plan, Palliative care

AOCNP study plan

8 weeks · About 6 hours per week

Week 1

Science of Oncology

  • Diagram the hallmarks of cancer and annotate how each hallmark maps to a therapeutic target class

  • Sequence the phases of the cell cycle and label the checkpoints, cyclins, and cyclin-dependent kinases that govern each transition

  • Contrast proto-oncogenes, oncogenes, and tumor suppressor genes, generating three named clinical examples of each

  • Outline the multistep model of carcinogenesis from initiation through promotion and progression, including the role of DNA repair defects

  • Interpret serum tumor markers and explain why each is used for monitoring rather than screening

Your checkpoint

One-page annotated cell-cycle and hallmark diagram plus a 25-item self-quiz scored at 80% or higher, with every miss rewritten as a corrected statement

Week 2

Science of Oncology & Cancer Treatment Modalities

  • Classify cytotoxic agents by mechanism of action and cell-cycle specificity without reference notes

  • Build a toxicity profile for each major drug class linking mechanism to expected adverse effect

  • Explain the four R's of radiobiology and distinguish external beam, brachytherapy, and systemic radiotherapy

  • Describe the signaling pathways targeted by small-molecule inhibitors and monoclonal antibodies

  • Predict which patients are candidates for a given targeted agent based on molecular findings

Your checkpoint

A drug class-to-mechanism-to-toxicity table covering at least 15 agents, verified against a primary oncology pharmacology source

Week 3

Cancer Prevention, Detection, and Diagnosis

  • Apply age- and risk-based screening recommendations to simulated patients across breast, colorectal, cervical, lung, and prostate cancer

  • Calculate and interpret sensitivity, specificity, positive predictive value, and negative predictive value from a 2x2 table

  • Assign TNM stage from a clinical vignette and state the corresponding stage group

  • Identify red flags for hereditary cancer syndromes and state the criteria that trigger genetic referral

  • Differentiate diagnostic, predictive, and prognostic biomarkers with a clinical example of each

Your checkpoint

A 20-vignette screening and diagnosis case set with written rationales for the correct and each distractor option

Week 4

Cancer Treatment Modalities & Supportive, Palliative, and End-of-Life Care

  • Distinguish the mechanisms of checkpoint inhibitors, CAR-T therapy, and bispecific antibodies, and outline immune-related adverse event management

  • Order multimodal treatment options for three common solid tumors and justify the sequence

  • Describe clinical trial phases, endpoints, and response criteria used to interpret published results

  • Compare autologous and allogeneic transplant indications, conditioning regimens, and major risks

  • Grade and manage common treatment toxicities using standardized grading criteria

Your checkpoint

A 75-item half-length practice exam completed under timed conditions with a score of 70% or higher and a categorized error log

Week 5

Supportive, Palliative, and End-of-Life Care

  • Select and combine antiemetic regimens by emetogenic risk level and patient-specific factors

  • Recognize and triage neutropenic fever, tumor lysis syndrome, spinal cord compression, superior vena cava syndrome, and hypercalcemia of malignancy

  • Construct an analgesic plan using the WHO ladder and perform an equianalgesic opioid conversion

  • Screen for and stage psychosocial distress, depression, and caregiver burden using validated tools

  • Conduct a structured goals-of-care and code status conversation using a defined communication framework

Your checkpoint

A two-page oncologic emergencies reference card plus a completed opioid conversion worksheet with five worked calculations

Week 6

Survivorship and Coordination of Care

  • Assemble the required elements of a survivorship care plan including surveillance schedule, late-effect risks, and health promotion

  • Identify secondary malignancy and cardiotoxicity risk by prior treatment exposure and set an appropriate screening interval

  • Apply fertility preservation and rehabilitation referral criteria at the point of diagnosis and after treatment

  • Screen for financial toxicity, insurance barriers, and medication adherence risk with actionable interventions

  • Coordinate handoff between oncology, primary care, and specialty services using a structured transition summary

Your checkpoint

A complete survivorship care plan drafted for a simulated early-stage breast cancer survivor, including surveillance calendar and late-effect screening

Week 7

Science of Oncology & Cancer Prevention, Detection, and Diagnosis & Cancer Treatment Modalities & Supportive, Palliative, and End-of-Life Care & Survivorship and Coordination of Care

  • Complete a full-length timed practice examination under test-day conditions

  • Categorize every incorrect item by domain and by error type (knowledge gap, misread, or reasoning error)

  • Re-teach the three weakest content areas using spaced repetition across at least three sessions

  • Convert high-yield facts into flashcards and review them to a 90% recall threshold

Your checkpoint

A domain-tagged error log with a written remediation plan and a prioritized top-20 weak-concept list

Week 8

Science of Oncology & Cancer Prevention, Detection, and Diagnosis & Cancer Treatment Modalities & Supportive, Palliative, and End-of-Life Care & Survivorship and Coordination of Care

  • Re-attempt every previously missed item and explain the correct rationale aloud without notes

  • Run three timed 25-item domain-specific drills targeting the weakest areas

  • Synthesize cross-domain content into a single condensed review sheet

  • Rehearse test-day logistics, pacing strategy, and anxiety management plan

Your checkpoint

A second full-length practice exam scored at 75% or higher plus a one-page high-yield synthesis sheet

Milestones

Week 2: Self-quiz on science of oncology and treatment modalities averaging 80% or higher across both weeks' quizzes

Week 4: Half-length timed exam completed with 70% or higher and an error log tagged by domain

Week 6: All five domains covered at least once with a completed survivorship care plan deliverable on file

Week 8: Full-length exam scored at 75% or higher with no domain below 65%

AOCNP exam day

Your checklist

Unexpired government-issued photo ID

Bring the primary ID your testing provider requires (typically a driver's license, passport, or state ID) with a signature and a name that matches your registration exactly, character for character. If your legal name recently changed, confirm with the provider before test day which documents they will accept.

Appointment confirmation and testing permit

Bring whatever admission document your scheduling confirmation tells you to present (confirmation number, authorization-to-test letter, or nothing at all if the center pulls you up by name). Confirm the exact requirement with the provider - do not assume.

Directions, parking, and a backup route

Save offline directions and the test center phone number. Know where to park and how long the walk from the lot to the suite takes, and identify a second route in case of transit delays or road closures.

An early arrival plan

Most testing centers ask candidates to arrive roughly 30 minutes before the appointment to complete check-in. Confirm the specific arrival window in your scheduling instructions; arriving late can mean forfeiting your seat and fee.

A plan for phone, smartwatch, and other devices

Expect to surrender or lock away all electronics. Leave the smartwatch at home or in the car, silence the phone before you enter the building, and know that touching a device during a break may be treated as a security violation. Confirm the center's storage policy in advance.

Layer-friendly clothing

Testing rooms are often cold or unevenly heated. Dress in layers you can remove without disturbing others, and choose something comfortable for several hours of sitting.

Water and a light snack for break time

Confirm whether the center gives locker or cubby access during breaks and whether food and drink are permitted outside the testing room. Avoid a heavy meal or excess caffeine right before the exam.

Eyeglasses, contact solution, and approved medical items

Bring your usual glasses rather than relying on tired eyes. If you need to keep medication, an inhaler, or a glucose monitor with you, request approval from the provider well before test day rather than at check-in.

Any permitted testing aids confirmed in writing

Do not bring a calculator, notes, or scratch materials unless your candidate handbook explicitly allows them and states how they are supplied. Confirm the allowed-aids list with the provider; bringing a prohibited item can void your score.

A note to stop learning new content

In the final day, review only condensed summaries of weak domains and your own prior missed-question notes. New material this late increases anxiety without improving recall.

Plan the day

72 hours before

Re-read the candidate handbook for ID, arrival, allowed-items, and break rules, and call or email the provider if anything is ambiguous. Confirm your appointment time, the test center address, and your travel plan. Take one final full-length practice set under timed conditions, then switch to light review of only your two weakest content areas.

48 hours before

Protect your sleep schedule: shift bedtime toward a normal hour and stop studying at least two hours before bed. Prepare your ID, confirmation document, clothing, and snack so nothing is left to decide later. Do not start a new resource.

24 hours before

Do a light pass through high-yield summaries - oncologic emergencies, common treatment toxicities, survivorship and supportive care, and pharmacology safety - for no more than 60 to 90 minutes total. Eat a normal dinner, avoid alcohol, set two alarms, and plan to arrive early. Stop studying by early evening.

Morning of

Eat a normal breakfast, hydrate moderately, and recheck that your ID and confirmation are in your bag. Arrive at the center early, use the restroom before check-in, silence and stow your phone, and expect to sign a confidentiality agreement and be photographed or fingerprinted at check-in. Do a brief breathing exercise rather than last-minute quizzing.

During the test

Read each question stem to the end before looking at the options, and answer every question - there is no credit for blanks and no penalty for guessing on a criterion-referenced exam. Flag and move past items that stall you, then return. Watch the on-screen clock and pace yourself against your target per-item time rather than against other candidates. Take a short break if you feel your focus slipping, remembering the clock keeps running, and use the provided scratch materials or on-screen tools only as permitted.

Rules to check

  • Bring the identification your provider requires and nothing else into the testing room; all personal belongings go into storage. If your ID is expired, damaged, or the name does not match your registration, you may be turned away and lose your fee.

  • Do not bring notes, study materials, phones, smartwatches, or any recording device into the testing area. Unauthorized items, or any attempt to photograph or reproduce exam content, can result in a voided score and a report to the certifying body.

  • Raise your hand and follow the administrator's instructions before leaving your seat for any reason. Unscheduled breaks generally do not stop the exam clock, so budget them deliberately - confirm the break rules for your exam with the provider.

  • Answer every question. Scoring is criterion-referenced against a passing standard rather than curved against other candidates, so there is no advantage to leaving an item blank.

  • Do not discuss, post, or reconstruct specific exam questions after the test. You will likely sign a confidentiality agreement at check-in, and violating it is a conduct issue independent of your score.

  • If you need a testing accommodation, a medical item at your seat, or a schedule change, request it from the provider well before test day. Requests raised at the test center generally cannot be granted.

  • Follow all instructions from test center staff and read the on-screen candidate agreement carefully. Report any technical problem or distraction to the administrator immediately rather than after the exam, because some remedies are only available in the moment.

  • Confirm how and when results are released, how long the certification is valid, and what the renewal requirements are directly with the certifying body rather than relying on secondhand information.

AOCNP FAQ

How many AOCNP practice questions are available?

The practice set has 200 AOCNP questions. Each one includes the choices, the correct answer, and an explanation, and the set is free to read with no signup.

How many AOCNP flashcards are available?

The flashcard set has 32 AOCNP cards. Each card shows the term and its definition.

Which topics does the AOCNP study material cover?

The AOCNP study material has 5 sections, including Science of Oncology: Carcinogenesis, Gene Classes, Growth Kinetics, and Metastasis, Cancer Prevention, Detection, and Diagnosis: Screening, Risk, Tissue, and Staging, and Cancer Treatment Modalities: Local Therapy, Systemic Agents, and Response Assessment.

What format facts does the catalog list for the AOCNP exam?

The catalog lists these item types: multiple choice for the AOCNP exam.